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Abstract 
Cardiovascular disease (CVD) is the leading cause of death in the United States. Arterial 
stiffness, left ventricular dysfunction, and left ventricular hypertrophy are risk factors for CVD 
and are measured by subclinical markers such as pulse pressure, left ventricular ejection fraction, 
and left ventricular mass index, respectively. Complex diseases, such as CVD, are caused by 
combination and interaction of various factors, such as genetic, epigenetic, and environmental 
factors. Although disease predisposition at the DNA level is rarely modifiable, the same genetic 
variant can be associated with various phenotypes in different environments. For example, 
epigenetic modification of DNA occurs naturally as a response to changes in environmental 
exposures. Thus, epigenetic modification may be considered as an intermediate phenotype which 
is a result of new kind of gene by environment interaction where the gene transcription is 
dependent on environmental factors. 
The goal of this dissertation is to provide insight into the mechanisms of CVD by 
combining information of genetic, epigenetic, and environmental factors. Specifically this 
dissertation investigates effect modification by candidate genetic polymorphisms and explores 
mediation analysis using epigenetic modification. First, this dissertation focuses on the effect 
modification by vitamin D receptor (VDR) genetic polymorphisms in the association between 
bone lead levels and pulse pressure in older unrelated non-Hispanic White men (Normative 
Aging Study) (Aim 1). Next, the focus is on the mediative effect of DNA methylation in the 
association between cigarette smoking and inflammation in older African American siblings 
(Genetic Epidemiology Network of Arteriopathy (GENOA)) using two-step epigenetic 
xvii 
 
Mendelian randomization (MR) approaches (Aim 2). The last part of this dissertation is 
dedicated to investigating the role of DNA methylation in cigarette smoking, inflammation, and 
subclinical markers of CVD in older African American siblings (GENOA) using network MR 
approaches and structural equation models (Aim 3). 
In Aim 1, we found that subjects with the minor frequency alleles of VDR Bsm1 or Taq1 
may be more susceptible to cumulative lead exposure-related elevated pulse pressure. Adjusting 
for potential confounders, pulse pressure was 2.5 mmHg (95% CI: 0.4-4.7) and 1.9 mmHg (95% 
CI: 0.1-3.8) greater per interquartile range increase in tibia lead (15µg/g) and patella lead (20 
µg/g), respectively, in those with at least one minor frequency allele in Bsm1 compared with 
those with major frequency allele homozygotes. In Aim 2, we identified that the odds ratio for 
current smoking was 1.96 for a one-unit increase in rs4887071 which results in 0.44 decrease in 
M-values of cg03636183 on F2RL3 gene, and a 5% increase in interleukin-18 (IL-18) levels 
(pg/ml), and results in 0.09 decrease in M-values of cg13500388 on CBFB gene and a 3% 
increase in C-reactive protein (CRP) levels (mg/L). In Aim 3, we found that direct effects of 
smoking were significant for log transformed CRP, log transformed interleukin-6 (IL-6), and 
fibrinogen. The direct effect of smoking was not significant for log(IL-18) levels. However, the 
indirect effect from smoking to log(IL-18) levels mediated by cg03636183 on F2RL3 gene, was 
significant. The indirect path had a significant effect on left ventricular mass index (LVMI). 
In summary, results suggest that VDR-related calcium metabolism pathways and DNA 
methylation play a role in adverse effects of cumulative lead exposure and cigarette smoking, 
respectively, on CVD. These findings together expand our understanding of mechanisms behind 
CVD development and can inform future studies. 
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Chapter 1 
Introduction 
This dissertation focuses on gene by environment interaction in risk factors of cardiovascular 
diseases (CVD). The introduction is composed of eight subsections to provide background on 
CVD in terms of its public health importance; risk factors of CVD focusing on smoking and 
inflammation; relevant subclinical markers including pulse pressure, left ventricular ejection 
fraction, and left ventricular mass index; genetic variation at the DNA level and epigenetic 
modification; relation to vitamin D and the vitamin D receptor (VDR) gene; relation to lead 
exposure; gene by environment interaction; and the Mendelian randomization (MR) approach. In 
the last section, the need to consider gene by environment interactions, through direct measures 
of environmental exposures or through indirect measures such as DNA methylation in response 
to environmental exposure to better understand variation in subclinical markers of CVD is 
highlighted. The overarching goal and hypotheses for each aim are presented last. 
Importance of Cardiovascular Disease 
CVD is the leading cause of death in the United States.1 In 2010, based on the National Vital 
Statistics Reports1, there were 780,213 deaths (age-adjusted death rate: 234 per 100,000) from 
CVD which accounted for 31.6% of total deaths. Age-adjusted death rates from CVD were 1.4 
times higher in men than in women (282 vs. 196 per 100,000) and were 1.3 times higher in 
African Americans than in non-Hispanic Whites (304 vs. 230 per 100,000).  
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In 2012, based on data from the National Health Interview Survey, the number of non-
institutionalized adults aged 18 and over who had been diagnosed with heart disease - coronary 
heart disease (CHD), angina, myocardial infarction (MI), or any other heart condition or disease 
- reached 26.6 million which equates to a prevalence of 11.3% (age adjusted: 10.8%).2 The 
prevalence went up to 24.4% among 65-74 year-olds, and 36.9% among 75 year-olds and over. 
The overall prevalence was higher in men (12.1%) than in women (9.7%). Six percent of adults 
aged 18 and over had been diagnosed with CHD, angina, or had a MI. The percentage was higher 
in men (7.6%) than in women (4.8%). Among adults aged 18 and over, 25.5% had been told they 
have hypertension or high blood pressure on two or more visits (age adjusted: 23.9%). The 
percentage went up to 52.3% among 65-74 year-olds, and 59.2% among 75 year-olds and over. 
Men (24.7%) were more likely to have hypertension than women (23.2%). African Americans 
(32.9%) were more likely to have hypertension than non-Hispanic Whites (22.9%). Therefore, it 
is important to study risk factors and biological/genetic mechanisms of the CVD among older 
individuals in various race/ethnic populations. 
Inflammation and Cardiovascular Disease 
Chronic systemic inflammation plays a key role in atherosclerosis development.3, 4 Smoking5 and 
alcohol consumption6 are two major environmental factors that can induce inflammatory 
responses. The levels of inflammatory biomarkers in the blood stream help to quantify the degree 
of inflammation and to predict future CVD events.7 Several inflammatory biomarkers that have 
been found to be associated with CVD events include C-reactive protein (CRP)8, 9, interleukin-6 
(IL-6)10, interleukin-18 (IL-18)11, 12, and fibrinogen.13, 14  
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C-reactive Protein 
CRP is produced as a non-specific acute response to inflammation, infection, and tissue 
damage.15 CRP is produced by hepatocytes under control of IL-6 and binds to lipids and 
lipoproteins;16 phospholipids on damaged cell membranes17 and apoptotic cells;18 and 
microorganisms.19 CRP activates generation and release of proinflammatory cytokines. CRP 
cannot recognize antigenic epitopes, however, it recognizes altered self-molecules and certain 
pathogens and provides early defense.20 In 468 healthy adult volunteers, the median of the serum 
CRP level was 0.8 mg/L with a range between 0.07 to 29 mg/L.21 In the study, over 90% of the 
study participants have serum CRP levels < 3mg/L. The distribution of serum CRP level is 
significantly different by gender and race/ethnicity: CRP was higher in African Americans than 
in European Americans, and it was higher in women than in men in the Dallas Heart Study.22 
Serum CRP level tends to increase with aging23 and it is useful in risk prediction of CVD 
events.8, 9, 24-26 
Interleukin-6 
IL-6 is produced by lymphocytes, monocytes, macrophages, adipocytes, endothelial cells, and 
vascular smooth muscle cells.27-29 This cytokine stimulates differentiation of B cells and T cells, 
and activation of NK cells and macrophages.30-32 IL-6 binds to and activates the IL-6 receptor, 
and the activated complex binds to the signal-transducing component of the membrane-bound 
receptor (gp130) and stimulates inflammatory responses.33 IL-6 has both pro-inflammatory and 
anti-inflammatory properties.34 IL-6 has anti-inflammatory effects on cells that express both IL-6 
receptor and gp130, while it has pro-inflammatory effects on cells that only express gp130. 
Chronic high IL-6 levels are largely determined by adipose tissue.35 Production of IL-6 is 
stimulated by CRP,36 and CRP expression in liver is stimulated by IL-6.37 Serum IL-6 levels are 
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associated with left ventricular dysfunction38-40 and cardiac hypertrophy.41, 42 It is a strong 
predictor of CVD events including mortality.43-45 
Interkeukin-18 
IL-18 is found at the sites of chronic inflammation and have been found to be expressed in 
various cell types including macrophages, dendritic cells,46 osteoblasts,47 intestinal mucosal 
cells,48 and synovial fibroblasts.49 Expression of the IL18 gene produces the inactive precursor of 
IL-18 which is activated by the endoprotease IL-1β (ICE)50 and protease 3.51 Active IL-18 can 
combine with IL-18 receptor, which is expressed in diverse cell types including macrophages52, 
neutrophils53, natural killer cells,54 and vascular endothelial cells.52 IL-18 is involved in 
regulation of innate and adaptive immunity.55, 56 It promotes production and release of 
cytokines,57 maturation of T cells and natural killer cells,58 and neutrophil activation.53 IL-18 
binding protein binds to IL-18 and inhibit the function of IL-18.59 Therefore, a careful 
consideration of the levels of IL-18, IL-18 receptor, and IL-18 binding protein is needed to 
estimate the activity of IL-18. IL-18 levels have been found to be associated with not only 
inflammatory diseases including rheumatoid arthritis,60 insulin-dependent diabetes mellitus (a.k.a. 
type 1 diabetes),61 multiple sclerosis,62 and inflammatory bowel disease,63, 64 but also other 
chronic diseases such as cancer,65 and CVD.11, 12 
Fibrinogen 
Fibrinogen is a coagulation factor that plays an important role in blood clotting.66 Fibrinogen is 
produced by hepatocytes in liver and is circulated through the blood stream.67 Damaged 
endothelial cells of blood vessels go through a coagulation cascade involving cleavage of 
fibrinogen by thrombin to form fibrin.68 Fibrinogen not only activates platelets and fibrin 
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formation, and increases serum viscosity, but also is involved in cytokine production and 
macrophage adhesion.69 Fibrinogen plays an important role in plaque formation and 
atherosclerosis70 and its level has been suggested as a predictor of CVD events.13, 14, 71 
Selected Subclinical Markers of Cardiovascular Disease 
Pulse Pressure and Arterial Stiffness 
 
Figure 1.1 Blood pressure measurements and pulse pressure. Adapted from Thorax 2008; 
63:306-311. 
 
Pulse pressure, the difference between peak systolic blood pressure (SBP) and end diastolic 
blood pressure (DBP), is a surrogate measure of arterial stiffness (Figure 1.1). Arterial stiffness 
is a loss of elasticity and compliance of arteries. Pulse pressure is an independent risk factor for 
CVD such as CHD, stroke, and heart failure.72-74 Pulse pressure has been demonstrated as an 
independent predictor of long-term cardiovascular mortality. Among the elderly, a 10 mmHg 
increase in pulse pressure has been associated with 10% to 25% increased risks for CVD-related 
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mortality including CHD, congestive heart failure, and cerebrovascular disease.75-77 In risk 
prediction of CHD for the middle-aged and elderly, pulse pressure performed better than SBP 
and DBP.78 In the Framingham Heart Study, as the study population became older, pulse 
pressure became more important in coronary risk prediction than SBP or DBP.79 Pulse pressure 
is the outcome in Aim 1. 
Left Ventricular Ejection Fraction and Systolic Function 
 
Figure 1.2 Left ventricular ejection fraction 
Left ventricular ejection fraction (LVEF), a measure of left ventricular systolic function, is 
calculated as a percentage of the amount of blood pumped out of the left ventricle compared to 
the total amount of blood in ventricle (Figure 1.2). LVEF ranges from 0% to 100%. LVEF 
between 55% and 70% is considered normal. A LVEF of 50% or lower is considered reduced 
and is associated with increased risk for heart failure, the most rapidly growing form of heart 
disease in the U.S, and sudden cardiac arrest, which claims 300,000 lives a year. As many as 20 
million Americans may have a reduced ejection fraction without any symptoms such a shortness 
of breath or fatigue. Causes of lower ejection fraction includes dilated cardiomyopathy, heart 
failure, problems with the heart’s valves, and long-standing uncontrolled high blood pressure.  
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  In a recent study of 850 coronary angiography patients, the Gensini score, a measure of 
the severity of coronary atherosclerosis, was associated with LVEF (β= -0.194, P<0.0001) 
independent of other risk factors including age, body mass index (BMI), blood pressure, fasting 
blood glucose level, blood lipids, and leucocyte count.80  In a study of 7,599 chronic heart failure 
patients, lower LVEF was associated with a greater risk of MI.81 Each 10% reduction in LVEF 
(below 45%) was associated with a significant increase in risk of all-cause death, cardiovascular 
death, sudden death, death due to heart failure, death due to MI, and other cardiovascular related 
deaths. LVEF is one of the outcomes in Aim 3. 
Left Ventricular Mass Index and Hypertrophy 
 
Figure 1.3 Cardiac hypertrophy. Adapted from 
http://www.columbiasurgery.org/hcm/diagnosis_hcm.html 
Left ventricular mass index (LVMI) is a marker of left ventricular hypertrophy (LVH) (Figure 
1.3).82 LVMI is calculated as left ventricular mass divided by body surface area83 or height2.7.84 
In a study of 40-59 years old men, the prevalence of LVH ranged from 2.7-3.2% in the 
normative group without hypertension while it ranged from 11.8-14.5% in the hypertensive 
group.85 In another study of an essential hypertensive population, the prevalence of LVH ranged 
from 59% to 73% depending on different criteria.86 Systemic inflammation and endothelial 
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damage in the blood vessel wall were associated with LVH.87 CRP level, a marker of 
inflammation, was positively associated with LVMI.88 LVMI has been suggested as a predictive 
marker for CVD events in the hypertensive population.89 LVMI is an outcome in Aim 3. 
Genetics of Cardiovascular Disease 
SNPs in Cardiovascular Disease 
Numerous studies have identified genetic polymorphisms that are associated with CVD and its 
risk factors. The very early large-scale genome-wide association study (GWAS) by the 
Wellcome Trust Consortium identified single nucleotide polymorphisms (SNPs) in the 9p21.3 
region associated with CHD in approximately 2,000 cases and 3,000 controls.90 For the most 
significant SNP, rs1333049, the reported odds ratio was 1.47 for heterozygotes and 1.9 for risk 
allele homozygotes. The discovery of the 9p21 region was confirmed in several other GWASs.91-
94 The 9p21 region has also been associated with other traits related to CVD such as ankle 
brachial index (ABI)95 and coronary artery calcification (CAC).96 A recent large-scale GWAS 
identified several new SNPs that are associated with CHD.97 According to the paper, the 
combined set of previously identified SNPs and newly identified SNPs explains 10% of genetic 
variance of CHD. The most significant SNPs in each region are more frequently found in 
regulatory regions such as 5’-untranslated regions than in inter-genic regions.98  
Based on the GWAS Catalog (http://www.genome.gov/gwastudies) by the National Human 
Genome research Institute (NHGRI), there were 174 SNPs (p-value ≤ 5E-8) found to be 
associated with cardiovascular disease by the end of May 2014.  
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DNA Methylation and Cardiovascular Disease Risks 
Epigenetic modification, including DNA methylation, histone acetylation and methylation, and 
RNA-associated silencing, can lead to changes in gene expression and phenotype without 
making changes to the DNA sequence. It is an important mechanism explaining the variation in 
phenotype observed among individuals with the same genotype. Some epigenetic patterns are 
inherited from parent to child but can be changed in response to environmental exposure. 
Epigenetic modification can explain the difference in phenotype between monozygotic twins.99 It 
also can explain changes in gene expression level and phenotype of the same individual over 
time.100  
 One example of epigenetic modification, DNA methylation, plays an important role in 
the development of atherosclerosis. In a study of knockout mice with deficiency in 
Methylenetetrahydrofolate reductase (MTHFR), global DNA hypomethylation was followed by 
the formation of aortic fatty streaks.101 Another mouse study also suggested that changes 
in global DNA methylation profiles are early markers of atherosclerosis and may play a 
causative role in atherosclerosis.102 The same study also showed that atherogenic lipoproteins 
promote global DNA hypermethylation in a human monocyte cell line. A change in methylation 
pattern is observed in the promoter region of genes such as extracellular superoxide dismutase, 
estrogen receptor-alpha, endothelial nitric oxide synthase and 15-lipoxygenase.103-106 
 A recent study investigated genetic-epigenetic interaction in CHD.107 The study was 
conducted in 253 unrelated subjects from the Verona Heart Project. The authors studied SNPs 
and DNA methylation levels in Factor VII (F7) gene, which is involved in the coagulation 
pathway and atherothrombosis. The methylation sites of the F7 gene were located at CpG islands 
and two known functional polymorphisms: a SNP (402 base-pair upstream of the gene, G>A) 
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and a 10 base-pair insertion (323 base-pair upstream of the gene). This study found that 
methylation of the SNP at the F7 gene promoter region reduced serum FVIIa concentration only 
among those with GG genotype (Pearson correlation coefficient between DNA methylation 
levels and serum FVIIa concentration = -0.201, p = 0.012) but not in other genotypes (p = 0.30). 
The CHD-free group showed higher methylation associated with lower FVIIa concentrations 
compared to the CHD group. The study suggests the possible role of genetic-epigenetic 
interaction in CHD development. In this dissertation, measures of DNA methylation are included 
in Aims 2 and 3. 
Vitamin D, Vitamin D receptor, and Cardiovascular Disease 
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Vitamin D and VDR 
Vitamin D2 and Vitamin D3 are two forms of vitamin D in the human body. Vitamin Ds are 
hydroxylated to 25-hydroxyvitamin D in the liver. An additional hydroxylation forms 1,25-
dihydroxyvitamin D (Figure 1.4). Vitamin D plays an important role in calcium metabolism.108 
Calcitriol (1,25-dihydroxyvitamin D), the active hormonal form of vitamin D, stimulates 
increased calcium absorption from the gut during calcium deficiency. It also stimulates the 
expression of genes engaged in absorption of calcium in the intestine. The effect of calcitriol is 
mediated by its interaction with the vitamin D receptor (VDR). The complex of calcitriol and 
VDR acts as a transcription factor regulating the gene expression of calcium-binding 
receptors.109 
Copyright © American Heart Association, Inc. All rights reserved. 
Figure 1.4 Vitamin D metabolism and activation to the steroidal hormone calcitriol. 
Adapted from Simpton R U Circulation. 2011; 124:1808-1810. 
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VDR and Cardiovascular Disease 
Importantly, vitamin D and the VDR are involved in not only calcium metabolism but also 
regulation of the cardiovascular system and development of CVD. VDRs are distributed in most 
of the body cells including cardiomyocytes, vascular smooth muscles, and endothelium of the 
blood vessels.110-112 In a rat study, expression of the VDR and enzymes involved in vitamin D 
synthesis and metabolism, 1-alpha-hydrozylase and 24-hydroxylase, increased in the 
hypertrophic heart.113 Cardiac myocytes isolated from VDR knockout mice show accelerated 
rates of contraction and relaxation.114 Deletion of the VDR gene in cardiomyocytes results in 
cardiac hypertrophy.115 Vitamin D has been demonstrated to regulate endothelial nitric oxide 
synthase and arterial stiffness in a mouse study.116 In apolipoprotein E knockout mice, vitamin D 
deficiency was associated with atherosclerosis.117 
The effect of VDR on immune response and inflammation has been related to 
atherosclerosis.118 Vitamin D levels are involved in arterial stiffness and arterial aging.119, 120 
Lower serum vitamin D3 level is known to be associated with hypertension.121 VDR is also 
involved in the renin-angiotensin system, cell proliferation and differentiation, anti-inflammation, 
and anti-fibrosis.122 Circulating vitamin D levels are found to be associated with left ventricular 
geometry and function, including ejection fraction, end-systolic diameter, and fractional 
shortening.123 Vitamin D supplementation is known to decrease the circulating level of pro-brain 
natriuretic peptide, a biomarker of CVD, and high-sensitivity CRP levels, a marker of 
inflammation.124 Vitamin D deficiency from either diet or genetic polymorphisms in the VDR 
gene has been associated with CVD.125-128 Based on a study of the National Health and Nutrition 
Examination Survey (NHANES) 2001 to 2004 data, prevalence of hypovitaminosis D (<30ng/ml) 
was associated with CHD (OR=1.48, 95%CI=(1.14, 1.91)).129 
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Genetics of the VDR 
The human VDR gene is 63 kilo base pairs long with 9 exons.130 Exon1 has 6 isoforms and 
alternative splicing of the VDR gene results in at least 14 transcript variants encoding different 
proteins.131 The VDR genetic polymorphisms are differentially distributed among ethnic 
populations with different linkage disequilibrium (LD) patterns.132 In the HapMap Phase II 
samples of 60 unrelated individuals from northern and western European origin (CEU) and 60 
unrelated Yoruba individuals (YRI) from Nigeria, the difference in allele frequency of SNPs in 
the VDR gene between the two ethnic populations ranges from 0.03 to 0.78 (Table 1.1). The 
distribution and size of haplotype blocks are also different among ethnic groups. The sizes of 
haplotype blocks are smaller in YRI than in CEU, as expected. The differences in allele 
frequencies could potentially explain, in part, some of the differences in prevalence of CVD and 
its risk factors between different ethnic groups. SNPs in the VDR gene are included in Aim 1. 
Lead  
Importance and measurement of Lead 
Lead exposure is a major public health issue and there are multiple sources of exposure including 
inhalation and ingestion of lead from indoor dust or outdoor soil, occupational exposures, hand-
to-mouth contact with lead-containing products for children, dust or chips of peeling lead-
containing paint, and ingestion of lead in drinking water conveyed through lead pipes.133 Recent 
reductions in the use of lead in gasoline, paint, and drinking water resulted in reduction in blood 
lead levels.134 However, even though blood lead levels have been gradually reduced since the 
phase-out of leaded gasoline in 1970s (blood lead levels in US population in 1976-1980 
(NHANES-II) and in NHANES 2007-2008 were 12.8µg/dL and 1.3 µg/dL, respectively),135 
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cumulative lead levels are still substantial in the elderly and associated with diverse diseases 
including cognitive function decline and CVD in the United States.136, 137 
Lead is a toxic heavy metal and lead toxicity is found in almost every system in the body. 
Over 90% of the total body lead burden in adults is accumulated in the bone and only about 1% 
is found in the blood.138 Blood lead is the most common biomarker of lead exposure levels in 
epidemiologic studies. While blood lead measurement reflects current or recent lead exposure 
levels, bone lead measurement is used as an index of cumulative lead exposure levels. Therefore, 
bone lead measurements serve as a better biomarker to study chronic disease.139 
Lead and Cardiovascular Disease 
Lead is known to increase the risk of CVD. Several studies have identified a positive association 
between lead exposure and hypertension, which is a major risk factor for CVD. Martin et al. 
found an association between blood lead levels and increases in blood pressure, as well as an 
association between tibia bone lead levels and hypertension in the Baltimore Memory Study.137 
Cheng et al. reported an increased risk of incident hypertension with higher levels of lead in tibia 
and patella bones using data from the Normative Aging Study (NAS).140 Another study, which 
used the NAS data, found an association between high lead levels in bone and blood and 
hypertension among subjects with low dietary calcium intake.141 Blood lead levels have also 
been associated with increased risk of pregnancy-induced hypertension.142 The association 
between lead exposure and the risk of hypertension in pregnant women was also demonstrated 
even in those with blood lead levels less than 2 μg/dL.143 
One of the biological processes that likely explains the association between lead exposure 
and the increased risk of CVD is  arterial stiffness, which is associated with aging and is 
accelerated by hypertension.144 Some studies have identified a positive association of lead 
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exposure with increases in pulse pressure, a measure of arterial stiffness, and with clinical CVD 
events. The study by Perlstein et al. suggests that lead accumulation may contribute to the 
increase in pulse pressure in the NAS.145 Zhang et al. also reported a deleterious impact of 
cumulative lead on pulse pressure with effect modification by hemochromatosis (HFE H63D) 
genetic polymorphism in the NAS.146 
Lead and VDR 
VDR is involved in lead absorption and accumulation. Vitamin D plays an important role in 
calcium metabolism, which is shared by lead.108 From its divalent cation characteristic, lead 
competes to bind to calcium-binding receptors.147 When calcium levels are low, the calcium-
binding protein may bind lead instead of calcium, resulting in elevated absorption of lead.148 The 
VDR genetic variants have been identified as potential genetic factors that can influence the 
absorption, retention and accumulation of lead in the human body.149 Schwartz et al. examined 
former organolead manufacturing workers and found that the VDR gene variant Bsm1 modifies 
the association between age and tibia bone lead levels.150 In this study, the cumulative level of 
lead in bone and the rate of reabsorption and excretion of lead over time were higher for those 
with the VDR Bsm1 variant. This study suggests that VDR genetic variant may play a role in 
susceptibility to lead accumulation.  
There have been studies examining effect modification of lead by VDR gene in relation to 
several diseases. Krieg et al. found that the association between lead and cognitive function was 
modified by VDR genetic variants, and the relationship between the serum homocysteine levels 
and blood lead concentrations varied by VDR genotypes.151 Weaver et al. reported that VDR 
genotypes modified the association between lead and serum creatinine level and the association 
15 
 
between lead and renal outcomes in lead workers.152 SNPs in the VDR gene are included in Aim 
1. 
Mendelian Randomization 
Observational epidemiologic studies have often suffered from confounding and reverse causation. 
The MR approach is a type of instrumental variable analysis,153 in which a genetic variant is used 
as an instrument variable to avoid biases from confounding and reverse causation.154 Genetic 
variants in DNA sequence, such as SNPs, may serve as an appropriate instrument because the 
meiotic assortment of genetic variants during gamete formation is random. As we are born with 
the randomly assigned genetic variants, common confounders such as age, gender, and 
socioeconomic status do not have effects on genetic variants. Therefore, using genetic variants as 
instruments for the exposure of interest helps to avoid confounding when we assess the 
relationship between an environmentally modifiable exposure and an outcome. Another 
advantage of MR is that we can make an inference on the direction of the association between 
two variables using a genetic variant as an instrument. The problem of reverse causation often 
exists in epidemiologic studies. For example, patients stop smoking or drinking alcohol after 
they are diagnosed for a disease. However, by assumption, the instrument has an effect on the 
outcome only through the exposure. Therefore, we can evaluate the direction of the association 
from one variable to another variable by randomizing one variable with genetic variants. Using 
an appropriate instrument enables us to make an inference that is comparable to randomized 
clinical trials while using observational epidemiologic studies. 
 The use of the MR approach can be limited by the availability of an appropriate 
instrument.155 A genetic variant that satisfies the following conditions can serve as an appropriate 
instrument: 1) the instrument has a causal effect (here the causal effect means directed effect 
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from instrument to exposure) on the (environmental) exposure, 2) the association between the 
instrument and the (disease) outcome is only through the exposure, and 3) the instrument does 
not share common causes (confounders) with the (disease) outcome. If there are no appropriate 
genetic variants that satisfy the conditions, the MR approach may not be able to provide stable 
unbiased estimates. Another limitation of this approach is a confounding that may be introduced 
by pleiotropic effects of genetic variants. Genetic variants often have pleiotropic effects, 
meaning that one genetic variant may have effects on several phenotypes. The pleiotropic effect 
may open other paths to the outcome resulting in introducing a bias in estimation. The MR 
approach is often less powerful than conventional regression approaches, hence, it may require a 
larger sample size.156   
 In spite of the limitations of the approach, the MR approach has become more widely 
used recently.157 Advances in genotyping and sequencing techniques have enhanced the 
availability of genetic variants as an instrumental variable. In addition, several extensions of the 
MR approach are becoming available and provide enhanced flexibility of the application of this 
approach.157  
Two-Step Epigenetic Mendelian Randomization 
Two-step epigenetic MR was proposed as an extension of the MR approach to integrate 
epigenetic modifications.158 DNA methylation is a kind of epigenetic modification. It is 
responsive to environmental exposures and plays an important role in regulation of gene 
expression.159 Therefore, DNA methylation can be considered as an intermediate phenotype that 
mediates between environmental exposure and disease outcome. The two-step epigenetic MR 
approach is composed of two steps of MR. The first step assesses the relationship between an 
environmental exposure and DNA methylation, and the second step assesses the relationship 
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between DNA methylation and an outcome. This approach requires instrumental variables for 
each step. Recent findings from methylation quantitative trait loci (MeQTL) studies support the 
idea of a genetic proxy for DNA methylation.160 In addition to that, recent epigenome-wide 
association studies (EWAS) identified differently methylated CpG sites by various 
environmental exposures supporting the mediating role of DNA methylation.161-164  
 The two-step epigenetic MR approach is limited by the availability of an appropriate 
instrument, confounding from pleiotropic effects, and reduced statistical power. However, this 
approach enables us to identify DNA methylation sites that mediate an environmental exposure 
and an outcome. The CpG sites of differential methylation can shed light on the 
biological/genetic mechanisms behind the elevated disease risk induced by an environmental 
exposure. The two-step MR approach is used in Aim 2. 
Network Mendelian Randomization 
The network MR approach is another extension of MR to investigate more complex paths of 
variables of interest.165 This approach enables us to estimate both direct and indirect effects of an 
exposure on an outcome. The method can be implemented using either a sequence of regressions 
or structural equation models (SEM).  
 This approach requires some additional assumptions to estimate direct and indirect 
effects166 using instrumental variables: 1) no interaction effect of exposure and mediator on 
outcome, 2) no bidirectional associations, and 3) sequential ignorability167 meaning that the 
exposure is statistically independent of the mediators and outcomes, and the mediator is 
statistically independent of the outcome given exposure and confounders. When the assumptions 
are satisfied, the network MR approach that is implemented using software for SEM provides 
extensive flexibility in applying the MR approach. Network MR is used in Aim 3.  
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Gene by Environment Interaction in Cardiovascular Disease 
Complex diseases, such as CVD, are influenced by a combination and interaction of various 
factors. Risk of CVD is affected by many factors including genetic variants, epigenetic 
modification, age, gender, race/ethnicity, smoking, alcohol consumption, diet, obesity, diabetes 
mellitus, physical activity, socioeconomic status, hypertension, dyslipidemia, arterial stiffness, 
left ventricular dysfunction, and environmental exposures like lead.168-170 Most studies focus on 
genetic variants ignore other factors or include them as confounders. In contrast, many studies 
that focus on environmental exposures or behaviors tend to ignore genetic variability among 
individuals. While a major assumption of many studies is that there is no gene-environment 
interaction, evidence exists for such interactions.171 
 Evidence for gene by environment interaction implies that the phenotype for a specific 
genotype depends on the environmental exposures. The environment may be measured directly, 
for example by cumulative lead exposure or self-reported smoking, or more indirectly by 
epigenetic modification in response to environmental exposures. Epigenetic modification occurs 
as a response to changes in environmental and lifestyle factors.172 Thus, epigenetic modification 
is known to explain, in part, the interaction between genes and environmental factors in 
development of various diseases including CVD.173-179 Epigenetic modification may be seen as 
an intermediate phenotype which is a result of the interaction between genes and environmental 
factors.  
Overarching goal 
The goal of this dissertation is to understand biological mechanisms of CVD using gene-
environment interaction. Specifically this dissertation examines effect modification by candidate 
genetic polymorphisms and explores mediation analysis using epigenetic modification on 
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measures of inflammation as well as CVD risk markers. Inflammatory biomarkers including 
CRP, IL-6, IL-18, and fibrinogen were considered. Pulse pressure, a measure of arterial stiffness, 
left ventricular ejection fraction (LVEF), a measure of systolic function, and left ventricular mass 
index (LVMI), a measure of left ventricular hypertrophy, are the subclinical markers of CVD 
risk and are the outcomes of interest. Aim 1 of this dissertation examines whether there is 
evidence for an interaction between VDR genetic polymorphisms and cumulative bone lead 
levels on pulse pressure in unrelated non-Hispanic White men. Aim 2 examines the mediating 
effect of DNA methylation on the relationship between smoking and inflammatory markers in 
African American siblings. Aim 3 investigates the causal paths of smoking, DNA methylation, 
and inflammatory markers extended to include subclinical markers of CVD in African American 
siblings.  
Hypothesis for Aim 1 
VDR genetic polymorphisms modify the association between cumulative bone lead exposure 
levels and longitudinal measures of pulse pressure. 
Hypothesis for Aim 2 
DNA methylation mediates the association between cigarette smoking and inflammatory markers. 
Hypothesis for Aim 3 
DNA methylation mediates the path from cigarette smoking to inflammation to either LVEF or 
LVMI.  
 
Studies on gene-environment interaction may shed light on identifying biological mechanisms 
underlying CVD development. The studies of gene-environment interaction in this dissertation, 
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using both directly measured environmental exposures, such as lead measurements, as well as 
indirectly measured environmental exposures, such as DNA methylation levels, together will 
further our understanding of the factors affecting CVD risk markers in diverse populations. 
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Tables 
Table 1.1 Allele frequencies of VDR genetic polymorphisms in the HapMap Phase II CEU 
and YRI populations. Partly adapted from Lins et al. Genet and Mol Biol. 2011; 34(3):377-
385. 
SNP Allele CEU YRI 
Difference in 
allele frequency 
rs4077869 A NA 0.40 NA 
rs11568820 (Cdx2) C 0.79 0.02 0.78 
rs4516035 A 0.58 0.99 0.41 
rs10783219 A 0.33 0.00 0.33 
rs7302235 A 0.74 0.43 0.31 
rs3890734 C 0.68 0.88 0.20 
rs2853559 A 0.42 0.17 0.25 
rs2853564 A 0.58 0.91 0.33 
rs2254210 C 0.63 0.66 0.03 
rs10735810 (FokI) C 0.53 0.83 0.31 
rs886441 A 0.81 0.58 0.23 
rs2239179 C 0.42 0.29 0.13 
rs2248098 A 0.43 0.38 0.04 
rs2239185 A NA 0.54 NA 
rs1544410 (BsmI) C 0.53 0.71 0.19 
rs7975232 (ApaI) G 0.42 0.38 0.05 
rs731236 (TaqI) A 0.53 0.75 0.22 
rs9729 G 0.41 0.34 0.08 
rs7968585 A 0.59 0.63 0.04 
rs11608702 A 0.36 0.18 0.18 
rs2544040 C 1.00 0.89 0.12 
SNP: Single Nucleotide Polymorphism; CEU: Northern and western 
European; YRI: Yoruba in Ibadan, Nigeria; Cdx2: caudal type homeobox 
2; NA: Not available 
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Chapter 2 
Effect modification by Vitamin D receptor genetic polymorphisms  
in the association between cumulative lead exposure and pulse pressure:  
a longitudinal study 
Introduction 
Lead (Pb) is known to increase the risk of cardiovascular diseases (CVD). A recent 
expert review by the National Toxicology Program (NTP) concluded that there is sufficient 
evidence that long-term cumulative exposure, even at low level exposure, which can be assessed 
by bone lead levels used in our study, is associated with elevated blood pressure.1 Several studies 
have identified a positive association between lead exposure and high blood pressure, which is a 
major risk factor for CVD. Martin et al2 found an association between blood lead levels and 
increases in blood pressure, as well as an association between tibia bone lead levels and 
hypertension in the Baltimore Memory Study. Cheng et al3 reported an increased risk of incident 
hypertension with higher levels of lead in tibia and patella bones in the Normative Aging Study 
(NAS).  Another study, which used the NAS data, found an association between high lead levels 
in bone and blood and hypertension among subjects with low dietary calcium intake.4 Blood lead 
levels have also been associated with increased risk of pregnancy-induced hypertension.5 The 
association between lead exposure and the risk of hypertension in pregnant women was also 
demonstrated even in those with blood lead levels less than 2 μg/dL.6 Lead exposure may also 
induce endothelial injury and atherosclerosis.7-9 The study by Perlstein et al10 suggests that lead 
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accumulation may contribute to the increase in pulse pressure, a measure of arterial stiffness, and 
with clinical cardiovascular events. Zhang et al11 also reported a deleterious impact of 
cumulative lead on pulse pressure with effect modification by hemochromatosis genetic 
polymorphism in the NAS.  
Vitamin D receptor (VDR) is involved in lead absorption and accumulation.12 Vitamin D 
plays an important role in calcium metabolism, which is shared by lead.13 Calcitriol, an active 
hormonal form of vitamin D, stimulates increased calcium absorption from the gut during 
calcium deficiency. Calcitriol also stimulates the expression of genes engaged in absorption of 
calcium in the intestine. The effects of vitamin D and calcitriol are mediated by their interaction 
with the VDR. The complex of calcitriol and VDR acts as a transcription factor regulating the 
gene expression of calcium-binding receptors. Because lead is a divalent cation, lead competes 
with calcium to bind to calcium-binding receptors.14 When calcium levels are low, the calcium-
binding protein may bind lead instead of calcium, resulting in elevated absorption of lead.15 The 
VDR genetic variants have been identified as potential genetic factors that can influence the 
absorption, retention and accumulation of lead in the human body.12 Schwartz et al. examined 
former organolead manufacturing workers and found that Bsm1 variant on the VDR gene 
modifies the association between age and tibia bone lead levels.16  In this study, the cumulative 
level of lead in bone and the rate of reabsorption and excretion of lead over time were higher for 
those with the VDR Bsm1 variant. This study suggests that the VDR genetic variant may play a 
role in susceptibility to lead accumulation.  
 Vitamin D and VDR are involved in arterial stiffness and arterial aging.17, 18 Vitamin D 
has been demonstrated to regulate endothelial nitric oxide synthase and arterial stiffness in a 
mouse study.19 Lower serum vitamin D3 levels are known to be associated with hypertension.20 
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VDR is also involved in the renin-angiotensin system, cell proliferation and differentiation, anti-
inflammation, and anti-fibrosis.21 The effect of VDR on immune response and inflammation has 
been related to atherosclerosis.22 
There have been studies examining effect modification of lead by VDR in relation to 
several diseases.23, 24 However, effect modification by VDR genotype in the association between 
lead and subclinical CVD measures, including arterial stiffness in longitudinal settings, has not 
yet been examined. In this study, we investigate effect modification by the VDR gene in the 
association between cumulative lead exposure measured by bone lead levels and pulse pressure, 
a marker of arterial stiffness. 
Methods 
Study population 
The Normative Aging Study (NAS) is a longitudinal study of the aging process established by 
the Veterans Administration in 1963 at the VA Outpatient Clinic in Boston, Massachusetts. The 
participants were 2,280 mostly White men aged 21 to 80 years with no past or present known 
chronic conditions (heart disease, cancer, recurrent asthma, sinusitis, bronchitis, diabetes, gout, 
peptic ulcer, or hypertension) 25. The NAS followed up on the participants every 3 to 5 years. 
 The NAS participants were invited to obtain bone lead measurements between 1991 and 
1999 at the Ambulatory Clinical Research Center of the Brigham and Women’s Hospital in 
Boston, Massachusetts (N=866). Of the participants with bone lead measurements, nine 
participants were excluded due to unreliable bone lead measurements (detailed description in the 
lead exposure section). Of 857 participants, 727 participants were successfully genotyped for at 
least one single nucleotide polymorphisms (SNP) on the VDR gene including Bsm1 (rs1544410), 
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Taq1 (rs731236), Apa1 (rs7975232), and Fok1 (rs10735810). The present analysis includes pulse 
pressure measured at the time of bone lead measurement (baseline, 1991-1999) and follow-up 
data through June 22, 2011. A total of 3,100 observations (727 participants) were used in this 
study. Each participating institute’s institutional review board approved this study and written 
informed consent was collected from each participant. 
Blood pressure 
The participants visited the study center in the morning. The participants were asked not to 
smoke or drink for at least 12 hours before a visit. Seating systolic blood pressure (SBP) and 
fifth-phase diastolic blood pressure (DBP) were measured to the nearest 2 mmHg. Blood 
pressures were measured in the left arm and then in the right arm with a standard mercury 
sphygmomanometer with a 14-cm cuff. The mean measurements of the left and right arms were 
used in this study. Pulse pressure was calculated as the difference between SBP and DBP. 
Lead exposure 
Bone lead measurement is used as an index of cumulative lead exposure levels. Tibia (the mid-
shaft of the left tibia, cortical) and patella (the left patella, trabecular) bone lead levels were 
measured using a K-x-ray fluorescence instrument (KXRF) (ABIOMED, Danvers, MA).26 
Participants with higher than 10 µg/g or 15 µg/g uncertainty of tibia or patella bone lead levels, 
respectively, (reflecting precision of the estimates) were excluded (n=9). More details were 
published in a previous study.27 
Genotyping 
Multiplex polymerase chain reaction assays were designed with Sequenom Spectro DESIGNER 
software (Sequenon, Inc, San Diego, CA) by inputting sequences containing the SNP site and 
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100 base pairs of flanking sequence on either side of the SNP. In the VDR gene, four single 
nucleotide polymorphisms (SNP) including Bsm1 (rs1544410), Taq1 (rs731236), Apa1 
(rs7975232), and Fok1 (rs10735810) were genotyped. More details on genotyping were provided 
in a previous study.27 
Statistical analysis 
When the data were investigated without assuming any inheritance models for the SNPs, we 
observed that a dominant inheritance model (in terms of minor frequency allele) fits the data best 
(data not shown). For dominant model, genotype was coded as 0 if a subject had no minor 
frequency allele (ancestral type), or was coded as 1 if a subject had one or two minor frequency 
alleles (variant type). The study population was partitioned based on the genotypes and 
compared with regard to baseline characteristics. For each of the four SNPs, the Hardy-Weinberg 
Equilibrium was checked for an evidence of inbreeding, population stratification, and problems 
in genotyping. 
To account for the repeated measurements on pulse pressure and covariates, linear mixed 
effects models with random intercepts were implemented. We decomposed age at examination 
into age-at-baseline and time-since-baseline to capture the baseline age effect as well as the 
longitudinal aging effect.28 The main effects of bone lead levels and VDR genotype, and their 
interaction term were fitted adjusting for time-since-baseline and an interaction term between 
time-since-baseline and bone lead levels in addition to the following covariates: age at baseline, 
race (White or not), body mass index (BMI), smoking (pack-years), alcohol intake (two or more 
drinks/day; Yes/No), calcium intake from food (calcium (mg) /day), diabetes status (Yes/No), 
antihypertensive medication status (Yes/No), family history of hypertension (Yes/No), education 
(less than high school, high school, some college, or four year college or more), and age at 
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baseline by VDR genotype interaction. The interaction between time-since-baseline and bone 
lead would capture different trajectories of pulse pressure over time in relation to bone lead 
levels. A three-way interaction among time-since-baseline, bone lead and VDR genetic 
polymorphism was initially considered but not included in our final model because it was almost 
null, suggesting that the lead by VDR genotype interaction did not change over time and that the 
lead by time-since-baseline interaction did not differ between the VDR genotypes. The mixed 
model we used is described as follows: 
𝑌𝑌𝑖𝑖𝑖𝑖 ~ 𝛽𝛽0 + 𝛽𝛽1 ∙ 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 + 𝛽𝛽2 ∙ 𝑆𝑆𝑆𝑆𝑆𝑆 + 𝛽𝛽3 ∙ 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 ∗ 𝑆𝑆𝑆𝑆𝑆𝑆 + 𝛽𝛽4 ∙ 𝑡𝑡𝑡𝑡𝑡𝑡𝑙𝑙 + 𝛽𝛽5 ∙ 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 ∗ 𝑡𝑡𝑡𝑡𝑡𝑡𝑙𝑙 +
𝑐𝑐𝑐𝑐𝑐𝑐𝑙𝑙𝑐𝑐𝑡𝑡𝑙𝑙𝑡𝑡𝑙𝑙𝑐𝑐 + 𝑢𝑢𝑖𝑖 + 𝜖𝜖𝑖𝑖𝑖𝑖 (𝐸𝐸𝐸𝐸𝑢𝑢𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝐸𝐸 1), 
where 𝑌𝑌𝑖𝑖𝑖𝑖 is pulse pressure of subject i at time j, 𝛽𝛽0 is a fixed intercept, 𝛽𝛽1 − 𝛽𝛽5 are fixed 
coefficients representing the estimated effects of each following term, 𝑢𝑢𝑖𝑖 is the random intercept 
that reflects unexplained subject to subject heterogeneity that induces correlation among 
observations from the same subject, and 𝜖𝜖𝑖𝑖𝑖𝑖 is a random error. 
To interpret longitudinal associations of pulse pressure with tibia levels, we computed the 
predicted values of pulse pressure from the model with the continuous tibia lead variable using 
the tibia bone lead values at the 25th percentile and the 75th percentile of the distribution at the 
baseline (time=0) and after 10 years of follow-up (time=10) for the ancestral type and variant 
type, with all covariates held constant at the mean (continuous variables) or zero (categorical 
variables). 
Results 
All the four SNPs on the VDR gene, Bsm1, Taq1, Apa1, and Fok1, are common SNPs with a 
minor allele frequency range of 0.37 to 0.45 (Table 2.1). All SNPs were in Hardy-Weinberg 
equilibrium. The Bsm1 is in a strong linkage disequilibrium (r2 = 0.92) with Taq1 in this study 
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population but not with Apa1 (r2 = 0.54) or Fok1 (r2 = 0.001). Genotypes missing rates were low 
(range: 1 - 6%). Among 727 participants, 442 participants (61%) had at least one copy of the 
Bsm1 minor frequency allele (bb or Bb, variant type) and 238 participants (33%) were 
homozygous for the major frequency allele (BB, ancestral type). Forty seven subjects (6%) had a 
missing Bsm1 genotype.   
The mean age at baseline of the study population was 66 years (range: 48-93 years). The 
participants were followed for up to 20 years. The median follow-up period was longer for 
subjects who had at least one copy of the Bsm1 minor frequency allele than for subjects who did 
not have the minor frequency allele (12 years vs. 9 years, Table 2.2). The number of follow-up 
examinations ranged from 1 to 8 with a median of 4. More than half of the participants were 
examined at least 5 times over 10 years.  
The subjects with a missing Bsm1 genotype were not substantially different from the 
remaining subjects for the baseline characteristics including age, race, BMI, SBP, DBP, pulse 
pressure, and blood pressure control medication status (Table 2.2). Tibia and patella bone lead 
levels, and the proportion of subjects with a family history of hypertension were slightly lower 
for those with the missing genotype. In contrast, calcium, sodium, potassium, and alcohol intake 
were slightly higher among subjects with the missing Bsm1 genotype. The baseline 
characteristics were similar between participants with ancestral type and those with variant type. 
Participants with ancestral type smoked more, had a higher DBP, and had slightly lower 
prevalence of whites. 
In longitudinal analyses, the association between bone lead levels and pulse pressure 
changed over time whereas the beta for the three-way interaction term of VDR genotype, bone 
lead and time-since-baseline was close to zero. This suggests that the association between bone 
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lead and pulse pressure changed over time but the difference in the association between bone 
lead and pulse pressure by VDR genotype was constant during the follow-up.  
Table 2.2 shows the estimated regression coefficients and 95% confidence intervals for 
the association between bone lead and pulse pressure by VDR genotype at baseline (i.e., time is 
fixed at zero). With an interquartile range (IQR) increase in tibia lead (15µg/g), pulse pressure 
was 2.5 mmHg (95% CI: 0.4-4.7) greater for the participants with variant type on Bsm1 
compared with the participants with ancestral type (Table 2.3). With an IQR increase in patella 
lead (20µg/g), pulse pressure was 1.9 mmHg (95% CI: 0.1-3.8) greater for the participants with 
at least one copy of the minor frequency allele in Bsm1 compared with the participants without 
the minor frequency allele (Table 2.4). Similar results were found for Taq1. The interaction 
effect was relatively smaller for Apa1 and Fok1.  
In Figure 2.1, we show the predicted values of pulse pressure from the model with the 
continuous tibia lead variable by Bsm1 genotype at baseline (time=0) and after ten years 
(time=10). At baseline, as tibia bone lead level increased from 13µg/g (25th percentile) to 28 
µg/g (75% percentile), pulse pressure increased by 0.07 mmHg (an IQR increase from 50.68 
mmHg to 50.75 mmHg) among subjects with Bsm1 ancestral type, while pulse pressure 
increased by 2.6 mmHg (from 49.68 mmHg to 52.28 mmHg) among subjects with Bsm1 variant 
type. After ten years, the marginal association (when the two lines were combined ignoring the 
Bsm1 genotype) between tibia bone lead levels and pulse pressure became weaker. After 10 
years of follow-up, as tibia bone lead level increased from 13µg/g (25th percentile) to 28 µg/g (75% 
percentile), pulse pressure decreased by 1.9 mmHg (from 54.09 mmHg to 52.19 mmHg) among 
Bsm1 ancestral type while pulse pressure increased by 0.63 mmHg (from 53.09 mmHg to 53.72 
mmHg) among Bsm1 variant type for the IQR change in tibia lead levels. In spite of the changing 
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association between bone lead levels and pulse pressure over time, the effect modifications by 
VDR Bsm1 and Taq1 genotypes on the association between bone lead levels and pulse pressure 
persists over time. 
We also conducted cross-sectional analyses using baseline data as a sensitivity analysis. 
The same covariates except time-since-baseline and its interaction with lead exposure levels 
were examined. Additional sensitivity analyses were done in order to investigate other possible 
confounders. Verifying analytical consistency, the interaction effect of bone lead levels and the 
VDR genotype on pulse pressure were examined by (i) adding the square of baseline age, (ii) 
adding sodium (Na) and potassium (K) intake, (iii) adding heart rate (sitting, beats/min), (iv) 
adding triglyceride level, (v) adding high-density lipoprotein (HDL) and total cholesterol-to-
HDL ratio, (vi) adding total calories (kcal/day) and physical activity (expended (fast walk 
adjusted), kcal/week), (vii) replacing BMI with height and waist circumference, (viii) replacing 
two alcohol drinks per day with grams per day of alcohol, (ix) replacing smoking in pack-years 
with current smoker or not, (x) ignoring calcium intake (obtained from a food frequency 
questionnaire), (xi) ignoring observations of subjects who are taking blood pressure control 
medication, and (xii) separating the blood pressure control medication variable into two variables: 
a calcium channel blocker and others. 
We found slightly larger beta values in the cross-sectional baseline analyses (Table 2.5). 
The magnitudes of the beta estimates slightly varied by different covariate sets but the 
conclusions were consistent (data not shown).  
Discussion 
Using longitudinal observations, we found a stronger association between cumulative bone lead 
levels and pulse pressure in participants with at least one minor frequency allele on Bsm1 or 
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Taq1. The results were consistent for tibia and patella bone lead levels. Our results were robust 
to cardiovascular risk related confounding factors in the sensitivity analyses. To our knowledge, 
this is the first study showing the interplay of VDR genetic polymorphisms and cumulative lead 
exposure levels on a CVD subclinical measure in the longitudinal setting. 
Pulse pressure is a marker of arterial stiffness, and elevated pulse pressure is a risk factor 
of CVD. Pulse pressure has been demonstrated as an independent predictor of long-term 
cardiovascular mortality. A 10 mmHg increase in pulse pressure has been associated with a 10 to 
25% increase in risk for CVD related mortality among older adults including coronary heart 
disease, congestive heart failure, and cerebrovascular disease.29-31 In the present study, we found 
that individuals with at least one VDR Bsm1 variant had a 2.5 mmHg greater pulse pressure in 
relation to every 15 µg/g increase in cumulative (tibia) lead exposure. We interpret this 
suggesting that individuals with VDR Bsm1 at least one variant may have 2.5% to 6% greater 
risks for CVD mortality for every 15 µg/g increase in cumulative lead exposure.  
The two genetic polymorphisms, that we found to interact with the cumulative lead 
exposure, are common SNPs with minor allele frequency over 0.4 in American Caucasians 
(Table 2.1). Over 65% of European descendants have at least one copy of these genetic 
polymorphisms, based on HapMap Phase 3 European ancestry samples,32 suggesting that over 65% 
of European descendants may be susceptible to cumulative lead exposure related elevation in 
pulse pressure. Thus, the lead by VDR interaction found in this study may explain some portion 
of CVD events and mortality in the elderly. 
Underlying biological mechanisms, by which the VDR genetic polymorphisms may 
modify the effect of lead on cardiovascular disease, are not well understood. Individuals with 
VDR genetic variants may have higher body burdens of lead, suggesting that the VDR gene may 
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modify the toxicokinetics of lead.12, 24, 33, 34 In a study of Korean lead workers, blood lead levels 
and tibia bone lead levels were significantly higher in participants with the VDR Bsm1 minor 
frequency allele.35 Another study of former organolead manufacturing workers in the eastern 
United States suggested that the VDR Bsm1 variant influences lead uptake and subsequent 
release of lead from bone.16 The interaction between the VDR and lead can be explained by 
calcium metabolism. The VDR plays a crucial role in calcium absorption and metabolism, which 
is shared by lead from its divalent cation characteristic. Calcium deficiency was demonstrated to 
increase lead absorption in the gastrointestinal tract in chicks.36, 37 Ingestion of lead inhibits the 
effect of vitamin D and its metabolites on intestinal calcium transport in rats.38 In addition, 
associations between high bone and blood lead levels and hypertension were also found among 
subjects with low dietary calcium intake in the NAS.4 
An interaction between the VDR gene and lead was also found to be involved in diverse 
disease development processes. In a study of the US general population,  adults aged 60 years 
and older with the VDR rs2239185–rs731236 (Taq1) CC haplotype showed  a negative 
association between blood lead and serum homocysteine, a risk factor of CVD and 
neurodegenerative disease, while those with the VDR rs2239185–rs731236 CT or TT showed a 
positive association.23 In the same study, adults aged 20 to 59 years of age who had 
VDR rs2239185–rs731236 CC or TT haplotypes, showed significant decline in cognitive 
function with increased blood lead concentration while those CT haplotype did not show 
significant decline. In a study of lead and creatinine among Korean lead workers, the VDR Bsm1 
genotype was also found to modify the association between tibia bone lead and renal function as 
assessed by serum creatinine level and creatinine clearance.24 The lead workers with at least one 
minor frequency allele on VDR Bsm1 showed worse renal function with higher lead exposure 
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levels. Another study of the Korean lead workers demonstrated an effect modification of the 
VDR Bsm1 genotype on the association between lead exposure and blood pressure.39 Among lead 
workers with the VDR Bsm1 variant, SBP were 2.7-3.7 mmHg higher and prevalence of 
hypertension was higher (OR =2.1).  Thus, our results and those of others support the concept of 
interaction between the VDR genotypes and lead.  
We observed a significant negative interaction between time-since-baseline and tibia 
bone lead levels in longitudinal analyses. The negative interaction can be interpreted in two 
different ways: the interaction effect between tibia bone lead and pulse pressure may decreases 
during the follow-up or the interaction effect between time-since-baseline and pulse pressure 
may decrease with higher lead exposure levels. A possible explanation for the decreasing effect 
of cumulative lead levels on pulse pressure during the follow-up is that people who had 
developed health related problems or diseases were more likely to drop out during follow-up.40 
Hence, the participants who stayed longer in the study may be healthier than those who dropped 
out. Another possible explanation is that other atherosclerotic risk factors became more 
pronounced as the study participants get older. As a result, the association between lead exposure 
and pulse pressure may seem attenuated over time. Alternatively, we have already reported that 
bone lead concentrations are falling in these participants, and more quickly for patella lead.41  
This suggests that the weaker associations between the baseline bone lead levels and the follow-
up pulse pressures could reflect the lower exposure at later follow-up visits. In spite of the 
changing association between bone lead levels and pulse pressure over time, our main interest, 
the effect modifications by VDR Bsm1 and Taq1 genotypes on the association between bone lead 
levels and pulse pressure were consistent over time (Figure 2.1). 
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 Figure 2.1 The predicted values of pulse pressure from the linear mixed model with the continuous tibia lead variable using 
the tibia bone lead values at the 25th percentile and the 75th percentile of the distribution at baseline (left) and after 10 years 
(right) for the ancestral type (solid line) and variant (dashed line), with all other covariates held constant at the mean 
(continuous variables: age at baseline (65yrs), BMI (28kg/m2), and calcium intake from food (800mg/day)) or zero (categorical 
variables: race (white), smoking (non-smoker), alcohol intake (less than two drinks/day), diabetes status (no), family history of 
hypertension (no), and education (completed high school)). 
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We see consistent results with regard to Bsm1 and Taq1. These SNPs are closely located 
to each other in the VDR gene (distance between Bsm1 and Taq1 = 1 kilo base pairs, size of the 
VDR gene = 63 kilo base pairs). The two SNPs are in high linkage disequilibrium (r2 = 0.92). 
Among participants with at least one minor frequency allele on Bsm1, 98% had at least one 
minor frequency allele on Taq1. This explains why Bsm1 and Taq1 show similar effect 
modification signals. And these consistent results support that our finding is less likely to be a 
false positive from genotyping errors on Bsm1 or Taq1. In the VDR gene, Bsm1 is located in 
intron8, and Taq1 is located in exon9. Genetic polymorphisms in intron regions, where splice 
enhances or silencers bind, can have an effect on alternative splicing.42 More than 60% of the 
alternatively spliced variants in humans results in changes in the protein structure which may 
result in conformational changes.43 However, whether these SNPs, Bsm1 and Taq1, are the 
functional polymorphism with an effect on the structure of vitamin D receptor or on the affinity 
of the receptor, or whether they are in high linkage disequilibrium with some other functional 
SNPs is unclear. It should be further investigated in animal studies or in vitro studies.  
The strengths of the current study include reliable bone lead measurements and extensive 
follow-ups up to 20 years (median follow-up of 9 years and median number of follow-up 
examinations of 4). The repeated measurements in pulse pressure and covariates increase 
statistical power to detect the gene by environment interactions. However, the NAS is an older 
cohort of predominantly white male participants. Hence, the findings may not be generalizable to 
women, younger individuals, and other ethnicities. 
Conclusion 
Lead toxicity is found in almost every system in the body. Over 90% of the total body 
lead burden in adults is accumulated in the bone and only about 1% is found in the blood.44 Even 
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though blood lead levels have been gradually reduced since the phase-out of leaded gasoline in 
the 1970s, cumulative lead levels are still substantial in the elderly and associated with diverse 
diseases including cognitive function decline and hypertension.2, 45. Our finding suggests that 
subjects with the minor frequency alleles of VDR Bsm1 or Taq1 may be more susceptible to 
cumulative lead exposure-related elevated pulse pressure. If the VDR gene is involved in the 
association between lead and pulse pressure, calcium metabolism may play an important role in 
lead toxicity in CVD. The observed interaction between cumulative lead levels and the VDR 
Bsm1 or Taq1 persists over time during the follow-up. This implies that the elderly experience 
adverse effects from their early lead exposure, even though current ambient lead levels are low. 
Our findings suggest the importance of restricting early exposure to lead to avoid its persistent 
adverse health effects in the subjects’ later life. 
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Tables 
Table 2.1 Characteristics of genetic markers in VDR gene. 
SNP Missing 
Number of  
minor frequency 
allele 
 MAF 
HWE HWE 
0 1 or 2 Statistics P-value 
Bsm1 47 (6%) 238 (33%) 442 (61%) 0.42 1.22 0.27 
Taq1 4 (1%) 242 (33%) 481 (66%) 0.41 0.76 0.38 
Apa1 7 (1%) 211 (29%) 509 (70%) 0.45 0.64 0.42 
Fok1 22 (3%) 274 (38%) 432 (59%) 0.37 0.25 0.62 
SNP: Single Nucleotide Polymorphism; MAF: Minor Allele Frequency; HWE: 
Hardy-Weinberg Equilibrium. 
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Table 2.2 Characteristics of study population by the number of genetic variants at baseline. 
Characteristics   Missing  
  
No. of minor frequency allele on Bsm1 
  
  All Bsm1 0 1 2 
Number of subjects 727 47 (6%) 238 (33%) 316 (43%) 126 (17%) 
Follow-up (years, mean±SD) 10.6±5.5 9.6±6.2 9.9±5.8 11.1±5.2 11.3±5.1 
No. of follow-up exams  (median (Q1-Q3)) 4 (3-6) 4 (2-6) 4 (2-6) 4.5 (3-6) 4.5 (3-6) 
Continuous variables (mean±SD) 
 
    Age at baseline (years) 66.4±7.2 66.8±8.9 66.7±7.1 66.1±7.1 66.6±6.9 
Height (m) 1.7±0.1 1.7±0.1 1.7±0.1 1.7±0.1 1.7±0.1 
Waist circumference (cm) 984.3±94.1 97.6±9.2 98.9±9.4 985.1±92.8 976.4±98.3 
Body Mass Index (kg/m2) 27.9±3.7 27.4±3.5 28.2±3.9 27.9±3.5 27.6±3.7 
High-density lipoprotein (HDL) cholesterol (mg/dL) 47.8±12.4 47.4±13.2 48.7±12.3 47.5±12.7 47.3±11.5 
Total cholesterol-to-HDL ratio 5.1±1.5 5.3±1.9 4.9±1.3 5.1±1.6 5.0±1.3 
Smoking (pack-years) 21.0±25.1 21.5±24.9 24.5±28.2 19.6±23.5 17.7±22.2 
Calcium intake (mg/day) 806±404 916±425 780±388 817±401 789±427 
Sodium intake (mg/day) 3855±1841 4022±1673 3770±1700 3970±2093 3658±1407 
Potassium intake (mg/day) 3363±1386 3895±1413 3212±1232 3467±1568 3191±1067 
Total calories intake (kcal/day) 1992±637 2208±770 1936±651 2015±615 1955±599 
Physical activity (kcal/week) 2002±1788 1963±1743 1879±1755 2131±1833 1921±1752 
Systolic blood pressure (mmHg) 136.0±17.3 135.5±18.2 137.6±17.9 135.2±17.8 135.3±14.4 
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Diastolic blood pressure (mmHg) 81.7±9.6 80.7±10.6 83.2±9.6 81.3±9.3 80.3±9.4 
Pulse pressure (mmHg) 54.3±14.7 54.8±15.9 54.5±14.5 53.8±15.3 55.0±12.8 
Tibia lead level (μg/g) 21.2±13.2 20.4±14.5 22.2±13.3 20.6±13.2 21.2±12.8 
Patella lead level (μg/g) 30.5±19.3 27.3±15.9 31.9±21.4 29.3±17.8 32.0±19.9 
Blood lead level (μg/dL) 5.9±3.9 6.0±4.4 6.5±4.1 5.7±3.7 5.6±3.7 
Categorical variables (n(%)) 
     
Race (white or not) 703 (97%) 45 (96%) 227 (95%) 310 (96%) 121 (96%) 
Alcohol ( two or more drinks/day) 148 (20%) 7 (15%) 42 (18%) 76 (24%) 23 (18%) 
Diabetes (diagnosed or taking medication) 94 (13%) 7 (15%) 28 (12%) 39 (12%) 20 (16%) 
Antihypertensive medication 128 (18%) 8 (17%) 44 (18%) 54 (17%) 22 (17%) 
Family history of hypertension 438 (60%) 21 (45%) 141 (59%) 201 (64%) 75 (60%) 
Education: Less than high school 70 (10%) 1 (2%) 31 (13%) 19 (6%) 19 (15%) 
                    Complete high school 248 (34%) 14 (30%) 87 (37%) 106 (34%) 41 (33%) 
                    Some college 179 (25%) 15 (32%) 53 (22%) 81 (26%) 30 (24%) 
                    College or more 204 (28%) 16 (34%) 62 (26%) 97 (31%) 29 (23%) 
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Table 2.3 Adjusted changes in pulse pressure (mmHg) with an IQR (15µg/g) increase in 
tibia lead levels. 
SNP N 
Ancestral vs. Variant Interaction term 
β (95% CI)* β (95% CI)* P 
Bsm1 
816 Ancestral 0.1 (-1.8, 1.9) 
2.5 ( 0.4, 4.7) 0.02 
1626 Variant 2.6 ( 1.2, 4.0) 
Taq1 
827 Ancestral 0.4 (-1.4, 2.2) 
2.0 (-0.1, 4.1) 0.06 
1760 Variant 2.4 ( 1.1, 3.8) 
Apa1 
795 Ancestral 1.5 (-0.4, 3.4) 
0.3 (-1.9, 2.4) 0.81 
1787 Variant 1.8 ( 0.4, 3.1) 
Fok1 
974 Ancestral 2.1 ( 0.5, 3.7) 
-0.02 (-2.0, 2.0) 0.99 
1548 Variant 2.1 ( 0.6, 3.6) 
SNP: Single Nucleotide Polymorphism; N: Number of observations; IQR: Inter-quartile range; 
P: p-value of the interaction term; Ancestral: major frequency allele homozygotes; Variant: 
minor frequency allele homozygotes and heterozygotes. 
*To compute effect estimates from longitudinal models, the time term was fixed at zero.   
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Table 2.4 Adjusted changes in pulse pressure (mmHg) with an IQR (20µg/g) increase in 
patella lead levels. 
SNP N 
Ancestral vs. Variant Interaction term 
β (95% CI)* β (95% CI)* P 
Bsm1 
811 Ancestral 0.0 (-1.6, 1.5) 
1.9 ( 0.1, 3.8) 0.04 
1619 Variant 1.9 ( 0.5, 3.2) 
Taq1 
822 Ancestral -0.1 (-1.6, 1.4) 
2.0 ( 0.2, 3.8) 0.03 
1753 Variant 2.0 ( 0.7, 3.3) 
Apa1 
789 Ancestral -0.1 (-1.8, 1.7) 
1.7 (-0.3, 3.6) 0.09 
1781 Variant 1.6 ( 0.4, 2.8) 
Fok1 
965 Ancestral 1.4 (-0.1, 2.9) 
0.3 (-1.5, 2.2) 0.72 
1545 Variant 1.7 ( 0.3, 3.1) 
SNP: Single Nucleotide Polymorphism; N: Number of observations; IQR: Inter-quartile range; 
P: p-value of the interaction term; Ancestral: major frequency allele homozygotes; Variant: 
minor frequency allele homozygotes and heterozygotes. 
*To compute effect estimates from longitudinal models, the time term was fixed at zero.   
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Table 2.5 Adjusted changes in pulse pressure (mmHg) with at least one minor allele in VDR gene per IQR increase in bone 
lead marker using baseline data. 
 
Tibia lead IQR = 15µg/g Patella lead IQR = 20µg/g 
  Wild vs. variant     Interaction term 
N 
Wild vs. variant   Interaction term 
SNP N β (95% CI) β (95% CI) P β (95% CI) β (95% CI) P 
Bsm1 612 
Ancestral -0.5 (-2.7, 1.7) 
3.0 ( 0.3, 5.8) 0.03 608 
Ancestral  0.5 (-1.4, 2.4) 
2.0 (-0.4, 4.4) 0.10 
Variant 2.6 ( 0.9, 4.2) Variant 1.5 (-0.1, 3.1) 
Taq1 649 
Ancestral -0.1 (-2.3, 2.1) 
2.4 (-0.3, 5.1) 0.08 645 
Ancestral -0.6 (-2.4, 1.2) 
2.1 (-0.2, 4.5) 0.07 
Variant 2.3 ( 0.7, 3.9) Variant 1.6 ( 0.0, 3.1) 
Apa1 647 
Ancestral  0.9 (-1.5, 3.3) 
0.7 (-2.0, 3.5) 0.60 603 
Ancestral -0.6 (-2.8, 1.6) 
1.6 (-0.9, 4.2) 0.20 
Variant 1.6 ( 0.1, 3.2) Variant 1.1 (-0.4, 2.5) 
Fok1 634 
Ancestral  2.1 ( 0.1, 4.1) 
-0.9 (-3.5, 1.7) 0.51 630 
Ancestral  1.1 (-0.7, 2.9) 
-0.5 (-2.8, 1.9) 0.71 
Variant 1.2 (-0.5, 3.0) Variant 0.6 (-1.0, 2.3) 
SNP: Single Nucleotide Polymorphism; N: Number of observations; IQR: Inter-quartile range; P: p-value of the interaction term; 
Ancestral: major frequency allele homozygotes; Variant: minor frequency allele homozygotes and heterozygotes. 
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Chapter 3  
Modeling the causal role of DNA methylation in the association  
between smoking and inflammation in African Americans 
Introduction 
Cigarette smoking is a well-known risk factor for many diseases including cardiovascular disease 
(CVD).1 Activation of inflammation has been suggested as a potential mechanism behind the 
smoking-induced cardiovascular risk.2 Efforts to identify genetic components involved in 
inflammatory response, which is induced by cigarette smoking, have been extended to 
epigenome-wide association studies (EWAS).3-7 Recently, epigenetic modification has gotten 
more attention in environmental epidemiology because of its plasticity and responsiveness to 
environmental changes.8 Epigenetic modification is one mechanism for regulation of gene 
expression levels.9 The most extensively studied epigenetic modification in human population is 
DNA methylation. DNA methylation is an addition of a methyl group to a Cytosine (C) base that 
is followed by a Guanine (G) base. C followed by G is denoted CpG where p indicates that C and 
G are connected by a phosphodiester bond.  DNA methylation levels in gene promoter regions 
are often inversely associated with gene expression levels of the gene.10 DNA methylation plays 
an important role in embryonic development,11 cell differentiation,12 and X chromosome 
inactivation.13  
Several EWAS identified differentially methylated CpG sites related to cigarette smoking 
status.3-7, 14 Methylation levels of the CpG sites in coagulation factor II (thrombin) receptor-like 3 
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(F2RL3), also known as protease-activated receptor 4 (PAR-4),3, 5, 14 and aryl-hydrocarbon 
receptor repressor (AHRR)4-6 have been consistently associated with cigarette smoking. However, 
the role of DNA methylation levels as a mediator in the association between cigarette smoking 
and inflammatory responses has not been investigated yet. Because of its responsive 
characteristic, DNA methylation may not only have an effect on inflammatory response, but also 
may be affected by inflammation. Therefore, DNA methylation brings another complexity from 
the possibility of reverse causation into the investigation.  
 The Mendelian randomization (MR) approach is an instrumental variable analysis using a 
genetic marker as an instrument. This approach enables us to examine the causal relationship in 
observational studies while avoiding confounding and reverse causation.15 Because of random 
assortment of genetic alleles during gamete formation, the assignment of a specific genetic allele 
is random. When a genetic marker is highly associated with the environmental exposure status, 
the assignment of environmental exposure using the genetic marker as an instrument can be 
considered as random. Therefore, the MR approach may be comparable to randomized clinical 
trials (RCT). Because we are born with the genetic allele, the genetic allele would not change by 
the environmental exposure status or other factors, therefore, the MR approach is less likely to be 
affected by confounding. In addition, the instrument has an effect on outcome only through the 
exposure by assumption,16 hence, we can evaluate the direction of the association from one 
variable to another variable by using the MR approach.  
In this study, we hypothesized that cigarette smoking is associated with DNA 
methylation levels, and DNA methylation levels are associated with inflammatory responses. To 
investigate the role of the DNA methylation as a mediator, we implemented the two-step 
epigenetic MR approach.17  
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Methods 
Study population 
The Genetic Epidemiology Network of Arteriopathy (GENOA) was established as a part of the 
Family Blood Pressure Program by the National Heart Lung and Blood Institute in 1996.18 From 
its inception, GENOA's long-term objective has been to elucidate the genetics of hypertension 
and its arteriosclerotic target-organ damage, including both atherosclerotic (macrovascular) and 
arteriolosclerotic (microvascular) complications involving the heart, brain, kidneys, and 
peripheral arteries. GENOA is a community-based study of sibships that incudes individuals 
with a personal or family history of hypertension.  
The African-American cohort of GENOA, which is the focus of Aims 2 and 3, is from 
Jackson, Mississippi.19 In Jackson, the sibships were recruited through hypertensive probands 
who had participated in the Atherosclerosis Risk in Communities (ARIC) study, which is a 
probability sample of 45 to 64-year-old African American residents of the community.20 At the 
enrollment stage of GENOA (Phase I: 1995-2000), 1,854 subjects who were members of 683 
sibships with at least two individuals diagnosed with essential hypertension before age sixty 
were recruited into the study. All siblings in the sibship were invited to participate, both 
normotensive and hypertensive. Exclusion criteria of the GENOA study were secondary 
hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or 
active malignancy. Eighty percent (1,482 subjects) of the initial study population returned for the 
second examination (Phase II: 2000-2005). Study visits were made in the morning after an 
overnight fast of at least eight hours. Data on demographic information, medical history, clinical 
characteristics, lifestyle factors, and blood samples were collected in each phase. Written 
informed consent was obtained from all subjects and approval was granted by participating 
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institutional review boards. Because both DNA methylation levels and inflammatory markers 
were measured at the second examination, only data from Phase II were used in this study. 
Genotypes 
For 1,263 participants, genotype data was obtained using the Affymetrix® Genome-Wide 
Human SNP Array 6.0 platform for about one million SNPs. For 269 samples, genotype data was 
obtained using Illumina® Human 1M-Duo BeadChip for about one million SNPs. For 508 
samples, genotype data was obtained using the Affymetrix® Genome-Wide Human SNP Array 
6.0 platform for about one million SNPs, separately. Quality control was performed based on the 
following exclusion criteria in order: <95% SNP call rate, <1% minor allele frequency (MAF), 
and <95% sample call rate.  
To get more dense markers, we imputed the genotype data using the 1,000 Genomes 
Project data.21 The three sets of samples were pre-phased and imputed separately. The DNA 
strands were aligned to positive strand. A physical map was updated from NCBI build 36 (hg 18) 
to build 37 (hg 19) using LiftOver software (http://genome.sph.umich.edu/wiki/LiftOver). Pre-
phasing was done using the Segmented HAPlotype Estimation and Imputation Tool (SHAPEIT) 
version 2.22  Pre-phasing was done separately for each chromosome. Imputation was performed 
using IMPUTE version 223 and reference panels from the 1,000 Genomes project Phase I 
integrated variant set release (v3) in NCBI build 37 (hg19) coordinates (released on March 2012).  
For imputation, each chromosome was split into 5 mega base pair (Mbp) long segments, 
resulting in 565 segments across the genome. Outlier samples from principal component 
analyses (>6 standard deviations) were excluded. Monomorphic markers were also excluded. 
Finally, there were 30,022,375 imputed SNPs for 1599 samples. 
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DNA methylation 
DNA methylation levels were measured from blood samples collected in Phase II. Peripheral 
blood leukocytes were isolated from blood samples and used to measure DNA methylation levels. 
The EZ DNA Methylation Gold Kit (Zymo Research, Orange CA) was used for bisulfite 
conversion. The methylation assay was performed at the Mayo Clinic Advanced Genomics 
Technology Center using Illumina® Infinium HumanMethylation27 BeadChips and Illumina 
BeadXpress reader. DNA methylation was measured from blood samples on a single array, in 
two different color channels (red and green). A total of 1,008 individuals were measured for 
27,578 CpG sites.  
As a quality control, seven samples were excluded from analysis due to poor bisulfite 
conversion efficiency (intensity < 4,000). An additional 28 samples were removed because of 
poor background signals. Finally, there were 973 samples left. The lumi package24 in R software 
was used for background adjustment, color balance adjustment, and quantile normalization. After 
quality control and normalization, the distribution of methylation intensity became similar across 
the samples. The CpG site intensities were used to calculate beta-values and M-values, a ratio of 
methylated allele intensity and total intensity+100, and a log2 ratio of methylated and 
unmethylated probe intensities, respectively.25 Cell proportions for CD8 T lymphocytes, CD4 T 
lymphocytes, natural killer cells, B cells, monocytes, granulocytes were estimated using 
Houseman’s method.26  
Smoking variable 
Current smoking status was obtained during Phase II from questionnaire asking a question “Do 
you now smoke cigarettes?”.  
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Inflammatory markers 
Inflammatory markers were measured from blood samples obtained during Phase II. Circulating 
CRP levels were measured by a highly sensitive immunoturbidimetric assay.27 Fibrinogen level 
was measured from citrated plasma using the clotting time based Clauss method.28 Interleukin-6 
(IL-6) and interleukin-18 (IL-18) were measured using a contracted service with SearchLight™ 
Technologies (Boston, MA).29 CRP, IL-6, and IL-18 were log-transformed to reduce skewness. 
Assumption checking 
A. Assumptions for instrumental variable analysis30 
a. The instrument has a causal effect (here causal effect means directed effect from 
instrument to exposure) on the exposure: genetic variants are rarely changed by other 
factors (except somatic mutations in cancer cells31). Therefore, any genetic variants that 
are statistically associated with the exposure satisfy this assumption. We have two 
instruments: one for smoking status (SNP S) and the other for DNA methylation levels 
(SNP C). To find SNP S that satisfies this assumption, the association between SNP S 
and smoking status was evaluated using the logistic mixed effects model with an alpha 
level of 0.05 (Equation 3.1).  
𝑙𝑙𝑐𝑐𝑙𝑙 �
𝑆𝑆1 − 𝑆𝑆� = 𝛽𝛽0 + 𝛽𝛽1 ∗ 𝑆𝑆𝑆𝑆𝑆𝑆 𝑆𝑆𝑖𝑖𝑖𝑖 + 𝛽𝛽2 ∗ 𝑙𝑙𝑙𝑙𝑙𝑙𝑖𝑖𝑖𝑖+ 𝛽𝛽3 ∗ 𝑙𝑙𝑙𝑙𝐸𝐸𝑙𝑙𝑙𝑙𝑐𝑐𝑖𝑖𝑖𝑖 + 𝑢𝑢𝑖𝑖   (𝐸𝐸𝐸𝐸𝑢𝑢𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝐸𝐸 3.1) 
where P is a probability of being a current smoker, 𝑢𝑢𝑖𝑖  is a random intercept for sibship j, 
and i indicates subject i.  
To check the assumption for SNP C, the association between the SNP C and DNA 
methylation levels was evaluated using the linear mixed effects model (Equation 3.2).  
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𝐷𝐷𝑆𝑆𝐷𝐷 𝑡𝑡𝑙𝑙𝑡𝑡ℎ𝑦𝑦𝑙𝑙𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝐸𝐸 𝑙𝑙𝑙𝑙𝑐𝑐𝑙𝑙𝑙𝑙𝑐𝑐= 𝛽𝛽0 + 𝛽𝛽1 ∗ 𝑆𝑆𝑆𝑆𝑆𝑆 𝐶𝐶𝑖𝑖𝑖𝑖 + 𝛽𝛽2 ∗ 𝑙𝑙𝑙𝑙𝑙𝑙𝑖𝑖𝑖𝑖 + 𝛽𝛽3 ∗ 𝑙𝑙𝑙𝑙𝐸𝐸𝑙𝑙𝑙𝑙𝑐𝑐𝑖𝑖𝑖𝑖 + 𝑢𝑢𝑖𝑖+ 𝜀𝜀𝑖𝑖𝑖𝑖   (𝐸𝐸𝐸𝐸𝑢𝑢𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝐸𝐸 3.2) 
where 𝑢𝑢𝑖𝑖  is a random intercept for sibship j, and 𝜀𝜀𝑖𝑖𝑖𝑖 is a random error for an individual i 
in sibship j.  
b. The association between the instrument and the outcome is only through the exposure. 
This assumption was checked by estimating a direct effect of the instrument on the 
outcome while the exposure is in the model. To check the assumption for SNP S, the 
direct effect of the SNP S on DNA methylation was assessed using the linear mixed 
effects model (with an alpha level of 0.05) including smoking status as a covariate 
(Equation 3.3). DNA methylation levels can be different depending on cell proportions. 
Hence, the model was adjusted for cell proportions.  
𝐷𝐷𝑆𝑆𝐷𝐷 𝑡𝑡𝑙𝑙𝑡𝑡ℎ𝑦𝑦𝑙𝑙𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝐸𝐸 𝑙𝑙𝑙𝑙𝑐𝑐𝑙𝑙𝑙𝑙𝑐𝑐= 𝛽𝛽0 + 𝛽𝛽1 ∗ 𝑆𝑆𝑆𝑆𝑆𝑆 𝑆𝑆𝑖𝑖𝑖𝑖 + 𝛽𝛽2 ∗ 𝑐𝑐𝑢𝑢𝑐𝑐𝑐𝑐𝑙𝑙𝐸𝐸𝑡𝑡 𝑐𝑐𝑡𝑡𝑐𝑐𝑠𝑠𝑡𝑡𝐸𝐸𝑙𝑙 𝑐𝑐𝑡𝑡𝑙𝑙𝑡𝑡𝑢𝑢𝑐𝑐𝑖𝑖𝑖𝑖+ 𝛽𝛽3 ∗ 𝑙𝑙𝑙𝑙𝑙𝑙𝑖𝑖𝑖𝑖 + 𝛽𝛽4 ∗ 𝑙𝑙𝑙𝑙𝐸𝐸𝑙𝑙𝑙𝑙𝑐𝑐𝑖𝑖𝑖𝑖 + 𝛽𝛽5 ∗ 𝐶𝐶𝐷𝐷8𝑇𝑇𝑖𝑖𝑖𝑖 + 𝛽𝛽6 ∗ 𝐶𝐶𝐷𝐷4𝑇𝑇𝑖𝑖𝑖𝑖 + 𝛽𝛽7 ∗ 𝑆𝑆𝑁𝑁𝑖𝑖𝑖𝑖+ 𝛽𝛽8 ∗ 𝐵𝐵𝑐𝑐𝑙𝑙𝑙𝑙𝑙𝑙𝑖𝑖𝑖𝑖 + 𝛽𝛽9 ∗ 𝑀𝑀𝑐𝑐𝐸𝐸𝑐𝑐𝑖𝑖𝑖𝑖 + 𝛽𝛽10 ∗ 𝐺𝐺𝑐𝑐𝑙𝑙𝐸𝐸𝑖𝑖𝑖𝑖 + 𝑢𝑢𝑖𝑖 + 𝜀𝜀𝑖𝑖𝑖𝑖   (𝐸𝐸𝐸𝐸𝑢𝑢𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝐸𝐸 3.3) 
where 𝑢𝑢𝑖𝑖  is a random intercept for sibship j, and 𝜀𝜀𝑖𝑖𝑖𝑖 is a random error for an individual i 
in sibship j. 
c. To check the assumption for SNP C, the direct effects of SNP C on inflammatory 
markers were assessed using the linear mixed effects models (with an alpha level of 0.05) 
including DNA methylation as a covariate (Equation 3.4). DNA methylation levels can 
be different depending on cell proportions. Hence, the model was adjusted for cell 
proportions.  
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𝐼𝐼𝐸𝐸𝐼𝐼𝑙𝑙𝑙𝑙𝑡𝑡𝑡𝑡𝑙𝑙𝑡𝑡𝑐𝑐𝑐𝑐𝑦𝑦 𝑡𝑡𝑙𝑙𝑐𝑐𝑠𝑠𝑙𝑙𝑐𝑐 𝑙𝑙𝑙𝑙𝑐𝑐𝑙𝑙𝑙𝑙𝑐𝑐= 𝛽𝛽0 + 𝛽𝛽1 ∗ 𝑆𝑆𝑆𝑆𝑆𝑆 𝐶𝐶𝑖𝑖𝑖𝑖 + 𝛽𝛽2 ∗ 𝐷𝐷𝑆𝑆𝐷𝐷 𝑡𝑡𝑙𝑙𝑡𝑡ℎ𝑦𝑦𝑙𝑙𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝐸𝐸 𝑙𝑙𝑙𝑙𝑐𝑐𝑙𝑙𝑙𝑙𝑐𝑐𝑖𝑖𝑖𝑖+ 𝛽𝛽3 ∗ 𝑙𝑙𝑙𝑙𝑙𝑙𝑖𝑖𝑖𝑖 + 𝛽𝛽4 ∗ 𝑙𝑙𝑙𝑙𝐸𝐸𝑙𝑙𝑙𝑙𝑐𝑐𝑖𝑖𝑖𝑖 + 𝛽𝛽5 ∗ 𝐶𝐶𝐷𝐷8𝑇𝑇𝑖𝑖𝑖𝑖 + 𝛽𝛽6 ∗ 𝐶𝐶𝐷𝐷4𝑇𝑇𝑖𝑖𝑖𝑖 + 𝛽𝛽7 ∗ 𝑆𝑆𝑁𝑁𝑖𝑖𝑖𝑖+ 𝛽𝛽8 ∗ 𝐵𝐵𝑐𝑐𝑙𝑙𝑙𝑙𝑙𝑙𝑖𝑖𝑖𝑖 + 𝛽𝛽9 ∗ 𝑀𝑀𝑐𝑐𝐸𝐸𝑐𝑐𝑖𝑖𝑖𝑖 + 𝛽𝛽10 ∗ 𝐺𝐺𝑐𝑐𝑙𝑙𝐸𝐸𝑖𝑖𝑖𝑖 + 𝑢𝑢𝑖𝑖 + 𝜀𝜀𝑖𝑖𝑖𝑖   (𝐸𝐸𝐸𝐸𝑢𝑢𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝐸𝐸 3.4) 
where 𝑢𝑢𝑖𝑖  is a random intercept for sibship j, 𝜀𝜀𝑖𝑖𝑖𝑖 is a random error for an individual i in 
sibship j, and inflammatory markers are log(CRP), log(IL-6), log(IL-18), and fibrinogen. 
d. The instrument does not share common causes with the outcome. Because genetic 
variants are rarely changed by other factors, this assumption is satisfied for any SNP. 
Two-step epigenetic Mendelian randomization 
In this study, we investigated the causal relation from smoking to inflammatory response 
mediated by DNA methylation using a two-step epigenetic MR approach (Figure 3.1).17 
Previous, a study of GENOA African Americans identified 15 CpG sites including cg03636183, 
cg19859270, cg04983977, cg13668129, cg13500388, cg13633560, cg03340878, cg01500140, 
cg00353953, cg11314684, cg03330058, cg13745870, cg17791651, cg14223444, and 
cg26259865 that were significantly associated with current smoking status (a derived binary 
variable on whether a participant smoked within the past year) (Bonferroni corrected p-value < 
0.05).14 Out of those 15 CpG sites, 5 CpG sites including cg03636183, cg19859270, cg13668129, 
cg01500140, and cg11314684 were significantly associated with current smoking status in an 
independent replication study. In our study, those 15 CpG sites found in GENOA study were 
considered. 
69 
 
 Figure 3.1. Two-step epigenetic Mendelian randomization. Rectangular dark boxes 
represent variables of interest at each step, and light boxes represent variables of interest 
at the other step. Solid arrows indicate the directed association of interest at each step, and 
dashed arrows indicate the directed association of interest at the other step. SNP S is an 
instrumental SNP for smoking, and SNP C is an instrumental SNP for DNA methylation 
levels of CpG sites. Equations 3.5-3.8 were used to obtain estimates at each step. 
Step 1: The MR approach was applied to examine the causal relationship between smoking and 
differential DNA methylation at the 15 CpG sites using selected SNPs (SNP S in Figure 3.1) as 
instrumental variables. Nicotinic acetylcholine receptor alpha3, alpha5, and beta4 genes 
(CHRNA3, CHRNA5, and CHRNB4) have been demonstrated to be associated with onset of 
smoking32, serum cotinine level 33, nicotine dependency 34, nicotine addiction 35, and smoking 
cessation success 36. We investigated SNPs within 10kb from CHRNA5, CHRNA3, and CHRNB4 
genes to identify an appropriate instrument SNP for step 1. Using logistic mixed effects models, 
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the SNPs were tested for an association with current smoking status adjusting for age, gender, 
and a random intercept for sibship effect. The allele dosage from imputation was used for SNPs 
assuming an additive inheritance model. Using the most significantly associated SNP with a 
MAF larger than or equal to 5% as an instrument, the MR approach was implemented by running 
two-stage least squares. First, current smoking status was regressed on the instrument SNP S 
using a logistic mixed effects model adjusting for age, gender, and a random intercept for sibship 
effect (Equation 3.5). Second, DNA methylation levels were regressed on the predicted values 
from equation 5 adjusting for age, gender, cell proportions, and a random intercept for sibship 
effect (Equation 3.6). 
𝑙𝑙𝑐𝑐𝑙𝑙 �
𝑆𝑆1 − 𝑆𝑆� = 𝛽𝛽0 + 𝛽𝛽1 ∗ 𝑆𝑆𝑆𝑆𝑆𝑆 𝑆𝑆 + 𝛽𝛽2 ∗ 𝑙𝑙𝑙𝑙𝑙𝑙+ 𝛽𝛽3 ∗ 𝑙𝑙𝑙𝑙𝐸𝐸𝑙𝑙𝑙𝑙𝑐𝑐 + 𝑢𝑢𝑖𝑖   (𝐸𝐸𝐸𝐸𝑢𝑢𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝐸𝐸 3.5)  
where P is a probability of being a current smoker, 𝑢𝑢𝑖𝑖  is a random intercept for sibship j, and i 
indicates subject i.  
𝐷𝐷𝑆𝑆𝐷𝐷 𝑡𝑡𝑙𝑙𝑡𝑡ℎ𝑦𝑦𝑙𝑙𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝐸𝐸 𝑙𝑙𝑙𝑙𝑐𝑐𝑙𝑙𝑙𝑙𝑐𝑐= 𝛽𝛽0 + 𝛽𝛽1 ∗ 𝑐𝑐𝑡𝑡𝑐𝑐𝑠𝑠𝑠𝑠𝐸𝐸𝑙𝑙� + 𝛽𝛽2 ∗ 𝑙𝑙𝑙𝑙𝑙𝑙 + 𝛽𝛽3 ∗ 𝑙𝑙𝑙𝑙𝐸𝐸𝑙𝑙𝑙𝑙𝑐𝑐+ 𝛽𝛽4 ∗ 𝐶𝐶𝐷𝐷8𝑇𝑇 +  𝛽𝛽5 ∗ 𝐶𝐶𝐷𝐷4𝑇𝑇 + 𝛽𝛽6 ∗ 𝑆𝑆𝑁𝑁 + 𝛽𝛽7 ∗ 𝐵𝐵𝑐𝑐𝑙𝑙𝑙𝑙𝑙𝑙 + 𝛽𝛽8 ∗ 𝑀𝑀𝑐𝑐𝐸𝐸𝑐𝑐 + 𝛽𝛽9 ∗ 𝐺𝐺𝑐𝑐𝑙𝑙𝐸𝐸+ 𝑢𝑢𝑖𝑖 + 𝜀𝜀𝑖𝑖𝑖𝑖    (𝐸𝐸𝐸𝐸𝑢𝑢𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝐸𝐸 3.6) 
where 𝑢𝑢𝑖𝑖  is a random intercept for sibship j, 𝜀𝜀𝑖𝑖𝑖𝑖 is a random error for an individual i in sibship j, 
and 𝑐𝑐𝑡𝑡𝑐𝑐𝑠𝑠𝑠𝑠𝐸𝐸𝑙𝑙�  is a predicted values from (Equation 3.5). 
To correct for the multiple testing problem, a Bonferroni correction was applied to the results of 
Step 1. Since fifteen DNA methylation sites were tested, 0.003 (=0.05/15) was used as a criterion 
for a significant p-value. 
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Step 2 The MR approach was applied to examine the causal relationship between DNA 
methylation and inflammatory responses using SNPs as instrumental variables.  We investigated 
SNPs within 10kb from the genes where the 15 CpG sites are located to identify appropriate 
instrument SNPs (SNP C in Figure 3.1) for step 2. Using linear mixed effects models, the SNPs 
were tested for an association with each of the CpG site methylation levels adjusting for age, 
gender, and a random intercept for sibship effect. Using the selected SNP as an instrument, the 
MR approach was implemented by running two-stage least squares. First, DNA methylation 
levels were regressed on the instrument SNP using linear mixed effects models adjusting for age, 
gender, and a random intercept for sibship effect (Equation 3.7). Second, inflammatory marker 
levels were regressed on the predicted values from equation 3.7 adjusting for age, gender, cell 
proportions, and a random intercept for sibship effect (Equation 3.8). 
𝐷𝐷𝑆𝑆𝐷𝐷 𝑡𝑡𝑙𝑙𝑡𝑡ℎ𝑦𝑦𝑙𝑙𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝐸𝐸 𝑙𝑙𝑙𝑙𝑐𝑐𝑙𝑙𝑙𝑙𝑐𝑐= 𝛽𝛽0 + 𝛽𝛽1 ∗ 𝑆𝑆𝑆𝑆𝑆𝑆 𝐶𝐶 + 𝛽𝛽2 ∗ 𝑙𝑙𝑙𝑙𝑙𝑙 + 𝛽𝛽3 ∗ 𝑙𝑙𝑙𝑙𝐸𝐸𝑙𝑙𝑙𝑙𝑐𝑐 + 𝑢𝑢𝑖𝑖 + 𝜀𝜀𝑖𝑖𝑖𝑖   (𝐸𝐸𝐸𝐸𝑢𝑢𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝐸𝐸 3.7) 
where 𝑢𝑢𝑖𝑖  is a random intercept for sibship j, and 𝜀𝜀𝑖𝑖𝑖𝑖 is a random error for an individual i in 
sibship j. 
𝐼𝐼𝐸𝐸𝐼𝐼𝑙𝑙𝑙𝑙𝑡𝑡𝑡𝑡𝑙𝑙𝑡𝑡𝑐𝑐𝑐𝑐𝑦𝑦 𝑡𝑡𝑙𝑙𝑐𝑐𝑠𝑠𝑙𝑙𝑐𝑐= 𝛽𝛽0 + 𝛽𝛽1 ∗ 𝑡𝑡𝑙𝑙𝑡𝑡ℎ𝑦𝑦𝑙𝑙𝑙𝑙𝑡𝑡𝑠𝑠𝑐𝑐𝐸𝐸� + 𝛽𝛽2 ∗ 𝑙𝑙𝑙𝑙𝑙𝑙 + 𝛽𝛽3 ∗ 𝑙𝑙𝑙𝑙𝐸𝐸𝑙𝑙𝑙𝑙𝑐𝑐+ 𝛽𝛽4 ∗ 𝐶𝐶𝐷𝐷8𝑇𝑇 +  𝛽𝛽5 ∗ 𝐶𝐶𝐷𝐷4𝑇𝑇 + 𝛽𝛽6 ∗ 𝑆𝑆𝑁𝑁 + 𝛽𝛽7 ∗ 𝐵𝐵𝑐𝑐𝑙𝑙𝑙𝑙𝑙𝑙 + 𝛽𝛽8 ∗ 𝑀𝑀𝑐𝑐𝐸𝐸𝑐𝑐 + 𝛽𝛽9 ∗ 𝐺𝐺𝑐𝑐𝑙𝑙𝐸𝐸+ 𝑢𝑢𝑖𝑖 + 𝜀𝜀𝑖𝑖𝑖𝑖    (𝐸𝐸𝐸𝐸𝑢𝑢𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝐸𝐸 3.8) 
where 𝑢𝑢𝑖𝑖  is a random intercept for sibship j, 𝜀𝜀𝑖𝑖𝑖𝑖 is a random error for an individual i in sibship j, 
𝑡𝑡𝑙𝑙𝑡𝑡ℎ𝑦𝑦𝑙𝑙𝑙𝑙𝑡𝑡𝑠𝑠𝑐𝑐𝐸𝐸�  is predicted values from (Equation 3.7), and inflammatory markers are log(CRP), 
log(IL-6), log(IL-18), fibrinogen. 
72 
 
For DNA methylation levels, beta-values have heteroscedasticity for highly methylated or 
unmethylated CpG sites. Thus, M-values were used as a primary measure due to their favorable 
statistical properties compared to beta-values.25 To resolve the multiple testing problem, a 
Bonferroni correction was applied to the results of the step 2 MR. To run the analysis, the lme() 
function in the nlme R package and SAS® 9.4 were used. 
Results 
Study population descriptive 
The total of 848 GENOA African-Americans with both measured genotypes and DNA 
methylation levels and were included in the analysis. The mean age was 67 years (standard 
deviation (SD) = 7 years), and 72% of the population were women. In this study population, 11% 
were current smokers, 30% were previous smokers, and 59% were never smokers. The majority 
of the study participants have been diagnosed for hypertension (77%), as expected (Table 3.1). 
Adjusting for age and gender, current cigarette smoking status was associated with inflammatory 
markers including log(CRP) (p = 0.03), log(IL-6) (p = 0.01), log(IL-18) (p = 0.06), and 
fibrinogen (p < 0.01).  
Assumption checking 
A.1. Assumption for the instrument SNP for smoking 
a. The instrument SNP is associated with the exposure.  
Among the 335 SNPs in the CHRNA5, CHRNA3, and CHRNB4 genes with MAF larger 
than or equal to 5%, rs4887071 was the most significantly associated with smoking status. 
The odds ratio (OR) for being a current smoker was 1.96 (95% CI: 1.12-3.42, p=0.02) for 
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every one copy of the minor allele of rs4887071 (minor allele = A, minor allele frequency 
= 7%) adjusting for age and gender in GENOA African Americans.  
b. The instrument SNP affects the outcome only through the exposure.  
The direct effect of rs4887071 on DNA methylation levels was not significant for 
methylation levels considered except for the CpG site in LIM2 (p<0.05) (Table 3.2). 
Therefore, the next SNP significantly associated with smoking, rs7170068 (minor allele 
frequency = 23%), was used as an instrument for LIM2. 
A.2. Assumption for instrument SNPs for DNA methylation 
a. The instrument SNP has an effect on the DNA methylation. To avoid a bias from a weak 
instrument, it is suggested to use an instrument with the F-value larger than 10.37 
Unfortunately, we could not find any instrument SNPs with F-value larger than 10 for 
cg03340878 in OR2B6, cg13745870 in SPATA12, cg13668129 in HNRPUL1, 
cg04983977 in GPR25, and cg19859270 in GPR15 (Table 3.3). We are aware of the 
possible bias from weak instruments for these CpG sites in the results. 
b. The instrument SNPs of DNA methylation affect the inflammatory responses only 
through the DNA methylation. All the instrument SNPs satisfy this assumption except 
rs11076844, which is an instrument SNP for LOC124220 and has a strong direct effect 
on log(CRP) levels (data not shown).  
 
Step 1 Mendelian randomization: Smoking -> DNA methylation 
In GENOA imputed genotype data using the 1000 genomes data as a reference panels, there 
were 997 SNPs within CHRNA5, CHRNA3, and CHRNB4 genes. To avoid selecting a rare 
variant as an instrument variable, we only considered 294 SNPs with a minor allele frequency 
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greater than or equal to 0.05. We tested the association between the 294 SNPs and current 
smoking status using logistic mixed effect models. The most significant SNP, rs4887071, was 
selected as the instrument for step 1 MR (p=0.02). The SNP has a F-value smaller than 10 and it 
may introduce a bias from weak instrument. To check the bias, a sensitivity analysis was 
performed using a genetic risk score that is composed of three SNPs with F-value of 13. The 
estimates and p-values were consistent using the genetic risk score (data not shown). The SNP, 
rs4887071, which is SNP S in Figure 3.1, is located in the intron region of CHRNB4 gene which 
makes a long-noncoding RNA (lncRNA). This lncRNA is a conserved target of microRNA (hsa-
miR-4659a-3p).38 Rs4887071 causes changes in the structure of the lncRNA which results in 
changes in the binding affinity between the lncRNA the microRNA (Figure 3.2).39, 40 The OR 
for being a current smoker is 1.96 (=e 0.67, 95% CI: 1.12-3.42) for every one copy of the minor 
allele of rs4887071 adjusting for age and gender in the GENOA African Americans. 
Figure 3.2. The effect of rs4887071 on the structure of lncRNA from CHRNA5 gene. The 
red arrow points out the bulge caused by rs4887071 
(http://bioinfo.life.hust.edu.cn/lncRNASNP/). 
Current smoking status was found to be associated with differential DNA methylation on 
the 15 CpG sites in GENOA.14 We reevaluated the association using the MR approach based on 
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Equations 3.5 and 3.6 (Table 3.4). Current smoking status, which is genetically affected by 
rs4887071, makes changes on DNA methylation levels of cg03636183 in F2RL3 gene, 
cg19859270 in GPR15 gene, cg13500388 in CBFB gene, and cg04983977 in GPR25 gene 
(criterion for p-value = 0.05/15 = 3.33E-03) (Table 3.4). With a minor allele of rs4887071, OR 
for current smoking was 1.96 which results in 0.44 (=log(1.96)*0.660) decrease in M-values of 
cg03636183 on F2RL3 gene. M-values of cg03636183 range between 0.12 and 5.13 with a mean 
of 3.06 (Table 3.5).  With a minor allele of rs4887071, OR for current smoking was 1.96 which 
results in 0.14 (=log(1.96)*0.203) decrease in M-values of cg19859270 on GPR15 gene. M-
values of cg19859270 ranges between -0.01 and 4.88 with a mean of 3.77. With a minor allele of 
rs4887071, OR for current smoking was 1.96 which results in 0.09 (=log(1.96)*0.138) decrease 
in M-values of cg13500388 on CBFB gene (M-value ranges between -1.47 and 1.94 with a mean 
of 0.32) and 0.06 (=log(1.96)*0.093) increase in M-values of cg04983977 on GPR25 gene (M-
values of ranges between -1.97 and 2.87 with a mean of 1.64). The results were mostly consistent 
between beta-values and M-values.  
Step 2 Mendelian randomization: DNA methylation -> Inflammation  
We further investigated whether the changes in DNA methylation levels induced by current 
smoking status can make changes in inflammatory responses. Adjusting for age and gender, the 
SNP that was the most significantly associated with the DNA methylation levels with a minor 
allele frequency larger than or equal to 5% was selected as an instrument for each CpG site based 
on Equation 2 (Table 3.3). Most of the SNPs, which were selected as instruments, were 
significantly associated with the methylation levels of each CpG sites. However, we could not 
find an appropriate instrument SNP for cg19859270 on GPR15 gene (p-value > 0.05). Because 
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there was no SNP that satisfied the assumptions for an instrument, cg19859270 was excluded for 
step 2. 
The three CpG sites, cg03636183 in F2RL3 gene, cg13500388 in CBFB gene, and 
cg04983977 in GPR25 gene that were found to be associated with smoking status in step 1 were 
considered in step 2 MR. We found that DNA methylation levels of a few CpG sites cause 
changes in inflammatory markers including IL-18 and CRP (Table 3.6).  
With a minor allele of rs4887071, OR for current smoking was 1.96 which results in 0.44 
decrease in M-values of cg03636183 on F2RL3 gene and 0.09 decrease in M-values of 
cg13500388 on CBFB gene. The 0.44 decrease in M-values of cg03636183 on F2RL3 gene 
results in a 5% (e 0.44*0.11=1.05) increase in IL-18 levels (pg/ml). The 0.09 decrease in M-values 
of cg13500388 on CBFB gene results in a 3% (e 0.09*0.30=1.03) increase in CRP levels (mg/L) 
(Table 3.7).  
Discussion 
The association between smoking and inflammation is well known.41 However, the biological 
mechanisms behind the association are not fully understood. In particular, the role of DNA 
methylation is largely unknown. We investigated the causal role of DNA methylation in the 
association between smoking and inflammation using the two-step epigenetic MR approach. We 
identified CpG sites that respond to smoking exposure and mediate the effect of smoking on 
inflammation. We demonstrated that current smoking status causes changes in DNA methylation 
levels of CpG sites on F2RL3, GPR15, CBFB, and GPR25 genes. Cg03636183 on the F2RL3 
gene has been found to be associated with smoking not only in GENOA and the Grady Trauma 
Project study but also in the Langzeiterfolge der KARdiOLogischen Anschlussheilbehandlung 
study and the Family and Community Health Study.3, 6, 14 Methylation in the F2RL3 gene has 
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been suggested as a biomarker of current and lifetime smoking exposure.42-44 Methylation of 
GPR15 was also found to be associated with current smoking, cumulative smoke exposure and 
time since smoking.45  
The methylation level changes of CpG sites on F2RL3 and CBFB genes are associated 
with changes in the levels of inflammatory markers IL-18 and CRP. The F2RL3 gene has been 
found to be associated with platelet activation and perioperative myocardial injury,46 post 
infectious irritable bowel syndrome,47 and gastric cancer.48 The CBFB gene makes a beta subunit 
of a core-binding transcription factor and it binds to Runt-related transcription factors (RUNX1, 2, 
and 3) that are involved in hematopoiesis and osteogenesis.49 The CBFB gene has been found to 
be associated with breast cancer, prostate and ovarian cancer, and acute myeloid leukemia.50-52  
Cigarette smoking has been associated with elevated levels of inflammatory markers. In a 
study of NHANES 1999-2002, current smokers had 36% (95% CI: 8-70%), 46% (95% CI: 10-
93%), and 73% (95% CI: 30-130%) higher levels of serum CRP among men aged 20-39, 40-59, 
60 and older, respectively, compared to non-smokers.53 Among smokers, a dose-response 
relationship was found between pack-years and serum CRP levels.54 High serum CRP and IL-18 
levels are associated with coronary artery disease and type 2 diabetes.55-57 
The two-step epigenetic MR approach enables us to identify the CpG sites that are 
involved in the association between an environmental exposure and an outcome. This approach 
can expand our understanding on the role of DNA methylation in disease development and 
provides information on biological mechanisms behind it. However, the MR has limitations. This 
approach relies on strong assumptions: every directed pathway from the instrument SNP to DNA 
methylation passes through smoking in step 1, and every directed pathway from the instrument 
SNP to inflammatory markers passes through DNA methylation. However, pleiotropic effects of 
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genes and SNPs that are found to be associated with human complex diseases and traits are 
abundant.58 Additional paths from the instrument SNP for smoking status to DNA methylation, 
and paths from the instrument SNP for DNA methylation to inflammatory markers can 
potentially introduce biases to the estimates from the MR approach. The MR approach also relies 
on the assumption that the relationship between variables is linear. Because a non-linear 
relationship is commonly found in epidemiologic studies,59 we might have missed a causal 
relationship which is not linear. Another limitation of this approach is the availability of an 
appropriate instrument. To avoid a bias from a weak instrument, it is suggested to use an 
instrument with the F-value larger than 10.37 However, the instrument SNP for cigarette smoking, 
and the instrument SNPs for DNA methylation levels of cg03340878, cg13745870, cg13668129, 
cg04983977, and cg19859270 (Table 3.3) had F-values smaller than 10. Use of those SNPs 
might introduce bias in effect size estimation. Statistical power of the MR approach is influenced 
by the strength of the association between an instrument and the exposure, and the association 
between the exposure and the outcome. Therefore, use of those SNPs with small F-values might 
also deteriorate statistical power of the MR approach. 
The other limitation of this study is that we did not consider the direct effect of smoking 
on inflammatory responses. To assess the magnitude and significance of the indirect effect of 
smoking that is mediated by DNA methylation levels, the MR approach should be applied in the 
framework of causal mediation analysis. In fact, a new method to study causal mediation with 
MR, named network MR, was recently published.60 The approach implemented in Aim 3 is 
similar to the newly published approach because both direct and indirect effects are considered to 
evaluate the causal mediation effect of DNA methylation.  
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 Compared to the general population, there are a relatively smaller number of current 
smokers in the elderly population. Smoking status is likely to be affected by infection or disease 
conditions. From the race/ethnic differences in prevalence of smoking and DNA methylation 
levels, the results may not be generalizable to other race/ethnic populations. The results may be 
better supported if the finding is confirmed in other independent study populations.  
In conclusion, we found evidence for the mediation of DNA methylation levels in the association 
between smoking and inflammation that will inform our next study using MR. 
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Tables 
Table 3.1 Descriptive characteristics of GENOA African American study population 
(N=848) at Phase 2 Examination. 
Continuous variables N Mean SD 
Age at examination (years) 848 67 7 
Height (cm) 844 168 9 
Weight (kg) 844 88 18 
Body Mass Index (kg/m2) 844 31 6 
Pack years 348 25 22 
Age started smoking 348 20 6 
Age quit smoking 252 48 12 
Alcohol (number of drinks/week) 122 4 4 
Education (years) 848 12 4 
Systolic blood pressure (sitting, mmHg) 848 154 22 
Diastolic blood pressure (sitting, mmHg) 848 92 12 
Pulse pressure (sitting, mmHg) 848 62 18 
C reactive protein (mg/L) 821 6 7 
Fibrinogen (mg/dL) 823 369 81 
Interleukin-6 (pg/ml) 741 10 7 
Interleukin-18 (pg/ml) 735 72 45 
High density lipoprotein (mg/dL) 848 59 18 
Low density lipoprotein (mg/dL) 848 121 38 
Lipid lp(a) (mg/dL) 823 63 51 
Categorical variables  N % 
Female  610 72% 
Current smoker  96 11% 
Previous smoker  252 30% 
Never smoker  500 59% 
Currently taking anti-hypertensive medication  634 75% 
Ever diagnosed with hypertension  661 78% 
Ever diagnosed with heart attack or MI  43 5% 
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Ever diagnosed with diabetes  249 29% 
Ever diagnosed with cancer  71 8% 
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Table 3.2 Estimates of direct effect of rs4887071 on DNA methylation levels (N=848). 
CpG site Gene Estimate SE Pr > |t| 
cg01500140 LIM2 0.08 0.04 0.03 
cg19859270 GPR15 -0.07 0.04 0.07 
cg13500388 CBFB -0.07 0.05 0.17 
cg03636183 F2RL3 -0.14 0.11 0.20 
cg13745870 SPATA12 -0.03 0.03 0.31 
cg04983977 GPR25 0.04 0.04 0.34 
cg03340878 OR2B6 -0.03 0.03 0.34 
cg03330058 ABTB1 -0.04 0.06 0.47 
cg13668129 HNRPUL1 -0.02 0.03 0.49 
cg17791651 POU3F1 0.05 0.07 0.49 
cg11314684 AKT3 0.02 0.04 0.55 
cg26259865 ZG16B -0.02 0.04 0.62 
cg14223444 NCBP1 -0.02 0.04 0.63 
cg00353953 ZNF384 0.00 0.05 0.92 
cg13633560 LRRC32 0.00 0.05 0.95 
ABTB1: ankyrin repeat and BTB (POZ) domain containing 1, AKT3:v-akt murine 
thymoma viral oncogene homolog 3, CBFB: core-binding factor beta subunit, F2RL3: 
coagulation factor II (thrombin) receptor-like 3, GPR15: G protein-coupled receptor 15, 
GPR25: G protein-coupled receptor 25, HNRPUL1: heterogeneous nuclear 
ribonucleoprotein U-like 1, LIM2: lens intrinsic membrane protein 2 (19kDa), ZG16B: 
zymogen granule protein 16B, LRRC32: leucine rich repeat containing 32, NCBP1: 
nuclear cap binding protein subunit 1 (80kDa), OR2B6: olfactory receptor, family 2, 
subfamily B, member 6, POU3F1: POU class 3 homeobox 1, SPATA12: spermatogenesis 
associated 12, ZNF384: zinc finger protein 384  
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Table 3.3 Instrument SNPs of 15 CpG sites to be used for step 2 Mendelian randomization 
(SNP C in Figure 3.1). 
CpG site Gene 
Step 2 
instrument 
SNP 
Coded 
allele 
frequency 
Estimate 
for SNP 
SE 
for 
SNP 
P-value 
for SNP 
F-
value 
cg13500388 CBFB rs8048014 0.15 0.59 0.02 8.69E-82 630 
cg03636183 F2RL3 rs2227341 0.19 -1.15 0.05 4.11E-71 505 
cg14223444 NCBP1 rs60028882 0.37 -0.20 0.01 1.24E-41 237 
cg03330058 ABTB1 rs7627836 0.16 -0.39 0.03 5.75E-30 155 
cg13633560 LRRC32 rs4945097 0.56 0.13 0.02 5.85E-10 40 
cg11314684 AKT3 rs10157763 0.15 0.13 0.02 4.51E-08 31 
cg26259865 LOC124220 rs11076844 0.83 -0.13 0.02 4.60E-08 31 
cg17791651 POU3F1 rs34860389 0.22 -0.19 0.03 5.02E-08 31 
cg00353953 ZNF384 rs35787939 0.06 0.20 0.04 3.53E-06 22 
cg01500140 LIM2 rs10409027 0.13 0.11 0.03 2.74E-04 14 
cg03340878 OR2B6 rs276364 0.07 0.08 0.02 2.50E-03 9 
cg13745870 SPATA12 rs9857168 0.84 -0.05 0.02 5.68E-03 8 
cg13668129 HNRNPUL1 rs12980267 0.14 -0.04 0.02 7.41E-03 7 
cg04983977 GPR25 rs2292099 0.8 0.04 0.02 3.55E-02 4 
cg19859270 GPR15 rs6790026 0.28 -0.03 0.02 1.08E-01 3 
 ABTB1: ankyrin repeat and BTB (POZ) domain containing 1, AKT3:v-akt murine thymoma viral 
oncogene homolog 3, CBFB: core-binding factor beta subunit, F2RL3: coagulation factor II 
(thrombin) receptor-like 3, GPR15: G protein-coupled receptor 15, GPR25: G protein-coupled 
receptor 25, HNRPUL1: heterogeneous nuclear ribonucleoprotein U-like 1, LIM2: lens intrinsic 
membrane protein 2 (19kDa), ZG16B: zymogen granule protein 16B, LRRC32: leucine rich 
repeat containing 32, NCBP1: nuclear cap binding protein subunit 1 (80kDa), OR2B6: olfactory 
receptor, family 2, subfamily B, member 6, POU3F1: POU class 3 homeobox 1, SPATA12: 
spermatogenesis associated 12, ZNF384: zinc finger protein 384  
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Table 3.4 Results of the step 1 Mendelian randomization (N=848) based on Equation 5 and 
6. 
 
  
Mendelian randomization 
(M-values) 
Mendelian randomization 
(Beta-values) 
CpG site Gene β SE P β SE P 
cg03636183 F2RL3 -0.660 0.087 <.0001 -0.059 0.007 <.0001 
cg19859270 GPR15 -0.203 0.029 <.0001 -0.010 0.002 <.0001 
cg13500388 CBFB -0.138 0.043 0.001 -0.023 0.007 0.001 
cg04983977 GPR25 0.093 0.030 0.002 0.012 0.004 0.006 
cg03340878 OR2B6 -0.070 0.025 0.005 -0.012 0.004 0.005 
cg01500140 LIM2 0.079 0.028 0.005 0.008 0.003 0.023 
cg03330058 ABTB1 -0.142 0.050 0.005 -0.022 0.008 0.005 
cg13668129 HNRPUL1 -0.057 0.021 0.006 -0.005 0.002 0.018 
cg13633560 LRRC32 -0.094 0.039 0.015 -0.012 0.005 0.012 
cg17791651 POU3F1 -0.085 0.050 0.087 -0.013 0.008 0.079 
cg26259865 LOC124220 -0.049 0.031 0.120 -0.007 0.004 0.085 
cg00353953 ZNF384 -0.050 0.033 0.130 -0.007 0.005 0.174 
cg13745870 SPATA12 -0.027 0.020 0.170 -0.005 0.004 0.173 
cg14223444 NCBP1 -0.018 0.027 0.510 -0.003 0.005 0.522 
cg11314684 AKT3 -0.010 0.030 0.750 -0.001 0.004 0.837 
ABTB1: ankyrin repeat and BTB (POZ) domain containing 1, AKT3:v-akt murine thymoma viral 
oncogene homolog 3, CBFB: core-binding factor beta subunit, F2RL3: coagulation factor II 
(thrombin) receptor-like 3, GPR15: G protein-coupled receptor 15, GPR25: G protein-coupled 
receptor 25, HNRPUL1: heterogeneous nuclear ribonucleoprotein U-like 1, LIM2: lens intrinsic 
membrane protein 2 (19kDa), ZG16B: zymogen granule protein 16B, LRRC32: leucine rich 
repeat containing 32, NCBP1: nuclear cap binding protein subunit 1 (80kDa), OR2B6: olfactory 
receptor, family 2, subfamily B, member 6, POU3F1: POU class 3 homeobox 1, SPATA12: 
spermatogenesis associated 12, ZNF384: zinc finger protein 384 
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Table 3.5 Distributions of M-values and Beta-values. 
  M-value 
  
Beta-value     
CpG Mean SD Min Max Mean SD Min Max 
cg03636183 3.06 0.96 0.12 5.13 0.88 0.08 0.51 0.97 
cg19859270 3.77 0.35 -0.01 4.88 0.93 0.02 0.45 0.97 
cg04983977 1.64 0.34 -1.97 2.87 0.75 0.05 0.19 0.88 
cg13668129 -2.19 0.24 -3.07 0.50 0.17 0.03 0.10 0.57 
cg13500388 0.32 0.49 -1.47 1.94 0.54 0.08 0.26 0.79 
cg13633560 -1.76 0.43 -3.71 -0.25 0.21 0.05 0.05 0.44 
cg03340878 -0.29 0.32 -1.83 1.08 0.44 0.06 0.20 0.67 
cg01500140 1.93 0.45 -1.35 3.15 0.79 0.05 0.27 0.90 
cg00353953 -1.28 0.39 -2.52 0.16 0.27 0.06 0.12 0.51 
cg11314684 -1.32 0.35 -2.85 0.36 0.28 0.05 0.11 0.56 
cg03330058 -0.71 0.54 -3.80 1.11 0.38 0.09 0.06 0.68 
cg13745870 0.07 0.27 -0.91 1.17 0.49 0.05 0.33 0.68 
cg17791651 0.90 0.59 -1.24 3.06 0.64 0.09 0.29 0.89 
cg14223444 -0.53 0.31 -1.49 1.87 0.40 0.05 0.25 0.77 
cg26259865 1.45 0.36 -3.35 2.93 0.73 0.05 0.08 0.88 
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Table 3.6 Results of the step 2 Mendelian randomization. 
   log (IL-6)  
N=741 
log (IL-18) 
N=735 
log (CRP) 
N=821 
Fibrinogen 
N=823 
CpG site Gene Estimate SE P Estimate SE P Estimate SE P Estimate SE P 
cg03636183 F2RL3 -0.02 0.04 0.51 -0.11 0.04 0.003 -0.05 0.06 0.400 -2.87 4.66 0.54 
cg13500388 CBFB -0.15 0.06 0.01 -0.06 0.06 0.300 -0.30 0.10 0.003 -15.80 7.69 0.04 
cg04983977 GPR25 0.44 0.17 0.01 0.27 0.18 0.140 0.51 0.30 0.090 46.10 22.82 0.04 
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Table 3.7 Effect of current smoking status on DNA methylation levels and inflammatory 
markers. 
  Step 1 Mendelian randomization 
Step 2 Mendelian 
randomization 
CpG site Gene Estimate SE P 
Change in 
M-value 
Inflammatory 
marker Change 
cg03636183 F2RL3 -0.660 0.087 <.0001 -0.44  IL-18 5% increase 
cg19859270 GPR15 -0.203 0.029 <.0001 -0.14   
cg13500388 CBFB -0.138 0.043 0.001 -0.09 CRP 3% increase 
cg04983977 GPR25 0.093 0.030 0.002 0.06   
CBFB: core-binding factor beta subunit, F2RL3: coagulation factor II (thrombin) receptor-like 3, 
GPR15: G protein-coupled receptor 15, GPR25: G protein-coupled receptor 25, IL-18: 
interleukin-18, CRP: C-reactive protein 
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Chapter 4  
Modeling causal direct and indirect effects of smoking  
mediated by DNA methylation on inflammation,  
and subclinical markers of cardiovascular disease 
Introduction 
Cigarette smoking induces inflammatory responses and is a risk factor for cardiovascular disease 
(CVD).1, 2 Cigarette smoking has been found to be associated with several inflammatory markers 
including C-reactive protein (CRP),3 interleukin 6 (IL-6),4 interleukin 18 (IL-18),5 and 
fibrinogen.6 However, the biological and genetic mechanisms behind the smoking-induced 
inflammatory response are not well understood.  
 DNA methylation has been found to be responsive to environmental changes and plays 
an important role in regulation of gene expression levels.7 In the previous study (Aim 2), we 
investigated the role of DNA methylation as a mediator of the association between smoking and 
inflammation. We identified specific CpG sites that had differential methylation levels by 
smoking status, and demonstrated the direction of the association from smoking to DNA 
methylation for cg03636183 in coagulation factor II (thrombin) receptor-like 3 (F2RL3) gene, 
cg19859270 in G protein-coupled receptor 15 (GPR15) gene, cg13500388 in core-binding factor 
beta subunit (CBFB) gene, and cg04983977 in G protein-coupled receptor 25 (GPR25) gene 
using Mendelian randomization (MR), an approach for utilizing a genetic variant as an 
instrument to examine a causal association in observational studies. The genetic variants were 
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single nucleotide polymorphisms (SNPs).  In addition, we examined the associations between 
DNA methylation levels of the identified CpG sites and levels of inflammatory markers, and 
demonstrated that the changes in DNA methylation levels are associated with the levels of 
inflammatory markers such as CRP and IL-18 using the two-step epigenetic MR approach.8   
Although the two-step MR is useful to assess an indirect effect that causally mediates the 
exposure-outcome association, it is limited in the evaluation of the magnitude of the indirect 
effect relative to the total effect. If there are several pathways from smoking to inflammation, it 
is likely that the estimates from the previous approach could be biased because it assumes the 
only path through the mediator of interest. Therefore, it is necessary to evaluate the mediated 
effect by DNA methylation in consideration of the possible direct effect. In this study, we 
combine the two-step epigenetic MR approach with causal mediation analysis, which is also 
known as the network MR approach.9 We also extended the network MR approach for more 
complex causal paths using structural equation modeling (SEM). 
In this study, we first investigated the direct and indirect effects of smoking on 
inflammatory markers through DNA methylation. Following that, the causal paths of smoking, 
DNA methylation, and inflammatory markers were extended to include subclinical markers of 
cardiovascular disease. 
Methods 
Study population 
The Genetic Epidemiology Network of Arteriopathy (GENOA) was established as a part of the 
Family Blood Pressure Program by the National Heart Lung and Blood Institute in 1996.10 From 
its inception, GENOA's long-term objective has been to elucidate the genetics of hypertension 
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and its arteriosclerotic target-organ damage, including both atherosclerotic (macrovascular) and 
arteriolosclerotic (microvascular) complications involving the heart, brain, kidneys, and 
peripheral arteries. GENOA is a community based study of sibships that incudes individuals with 
a personal or family history of hypertension. The African-American cohort of GENOA, which is 
the focus of Aims 2 and 3, is from Jackson, Mississippi.11 In Jackson, the sibships were recruited 
through hypertensive probands who had participated in the Atherosclerosis Risk in Communities 
(ARIC) study, which is a probability sample of 45 to 64-year-old African American residents of 
the community.12 At the enrollment stage of GENOA (Phase I: 1995-2000), 1,854 subjects who 
were members of 683 sibships with at least two individuals diagnosed with essential 
hypertension before age sixty were recruited into the study. All siblings in the sibship were 
invited to participate, both normotensive and hypertensive. Thus, everyone had a personal or 
family history of hypertension.  Exclusion criteria of the GENOA study were secondary 
hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or 
active malignancy. Eighty percent (1,482 subjects) of the initial study population returned for the 
second examination (Phase II: 2000-2005). Study visits were made in the morning after an 
overnight fast of at least eight hours. Data on demographic information, medical history, clinical 
characteristics, lifestyle factors, and blood samples were collected in each phase. Written 
informed consent was obtained from all subjects and approval was granted by participating 
institutional review boards. Because both DNA methylation levels and echocardiograms were 
measured at the second examination, only data from Phase II were used in this study. 
Genotypes 
For 1,263 participants, genotype data was obtained using the Affymetrix® Genome-Wide 
Human SNP Array 6.0 platform for about one million SNPs. For 269 samples, genotype data was 
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obtained using Illumina® Human 1M-Duo BeadChip for about one million SNPs. For 508 
samples, genotype data was obtained using the Affymetrix® Genome-Wide Human SNP Array 
6.0 platform for about one million SNPs, separately. Quality control was performed based on the 
following exclusion criteria in order: <95% SNP call rate, <1% MAF, and <95% sample call rate.  
To get more dense markers, we imputed the genotype data using the 1,000 Genomes 
Project data.13 The three sets of samples were pre-phased and imputed separately. The DNA 
strands were aligned to positive strand. A physical map was updated from NCBI build 36 (hg 18) 
to build 37 (hg 19) using LiftOver software (http://genome.sph.umich.edu/wiki/LiftOver). Pre-
phasing was done using the Segmented HAPlotype Estimation and Imputation Tool (SHAPEIT) 
version 2.14  Pre-phasing was done separately for each chromosome. Imputation was performed 
using IMPUTE version 215 and reference panels from the 1,000 Genomes project Phase I 
integrated variant set release (v3) in NCBI build 37 (hg19) coordinates (released on March 2012).  
For imputation, each chromosome was split into 5 mega base pair (Mbp) long segments, 
resulting in 565 segments across the genome. Outlier samples from principal component 
analyses (>6 standard deviations) were excluded. Monomorphic markers were also excluded. 
Finally, there were 30,022,375 imputed SNPs for 1599 samples.  
DNA methylation 
DNA methylation levels were measured from blood samples collected in Phase II. Peripheral 
blood leukocytes were isolated from blood samples and used to measure DNA methylation levels. 
The EZ DNA Methylation Gold Kit (Zymo Research, Orange CA) was used for bisulfite 
conversion. The methylation assay was performed at the Mayo Clinic Advanced Genomics 
Technology Center using Illumina® Infinium HumanMethylation27 BeadChips and Illumina 
BeadXpress reader. DNA methylation was measured from blood samples (obtained in the second 
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examination) on a single array, in two different color channels (red and green). A total of 1,008 
individuals were measured for 27,578 CpG sites.  
As a quality control, seven samples were excluded from analysis due to poor bisulfite 
conversion efficiency (intensity < 4,000). An additional 28 samples were removed because of 
poor background signals. Finally, there were 973 samples left. The lumi package16 in R software 
was used for background adjustment, color balance adjustment, and quantile normalization. After 
quality control and normalization, the distribution of methylation intensity became similar across 
the samples. The CpG site intensities were used to calculate beta-values and M-values, a ratio of 
methylated allele intensity and total intensity+100, and a log2 ratio of methylated and 
unmethylated probe intensities, respectively.17 Cell proportions for CD8 T lymphocytes, CD4 T 
lymphocytes, natural killer cells, B cells, monocytes, granulocytes were estimated using 
Houseman’s method.18 
Smoking variable 
Current smoking status was obtained during Phase II from questionnaire asking a question “Do 
you now smoke cigarettes?”.  
Inflammatory markers 
Inflammatory markers were measured from blood samples obtained during Phase II. Circulating 
C-reactive protein (CRP) levels were measured by a highly sensitive immunoturbidimetric 
assay.19 Fibrinogen level was measured from citrated plasma using the clotting time based Clauss 
method.20 Interleukin-6 (IL-6) and interleukin-18 (IL-18) were measured using a contracted 
service with SearchLight™ Technologies (Boston, MA).21 CRP, IL-6, and IL-18 were log-
transformed to reduce skewness. 
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Echocardiogram 
Echocardiograms were performed at the second examination in Jackson. Two-dimensional, M-
mode, and Doppler echocardiography was performed at the Echocardiography Laboratory in the 
Mayo Clinic using an Acuson 128XP echo machine (Acuson, Malvern, PA).22, 23 The parasternal 
long axis view was used to measure left ventricular ejection fraction. Penn and American Society 
of Echocardiography (ASE) conventions and the cube function formula was used to measure left 
ventricular mass.24 Left ventricular mass index was obtained by normalizing the left ventricular 
mass to height2.7.25 
Data Analysis 
The allele dosage from imputation was used for SNPs assuming an additive inheritance model. 
For DNA methylation levels, M-values were used as a primary measure because M-values have 
better statistical validity than beta-values.17 To take into account the correlation among siblings, 
mixed effects models with a random intercept were implemented. Assumption checking was 
done using the nlme R package and SAS® 9.4. Application of network MR was done using Stata 
13. 
Causal mediation analysis with instrumental variables 
We assessed the indirect effect mediated by DNA methylation in comparison to the direct effect 
of smoking on inflammatory response by implementing a causal mediation analysis with 
instrumental variables (Figure 4.1).  
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Figure 4.1. Application of Network Mendelian randomization on smoking, DNA 
methylation (Me-CpG), and inflammation. Rectangular boxes represent variables of 
interest and arrows represent causal relationships. SNP S is an instrument for smoking 
status and SNP C is an instrument for DNA methylation of a CpG site.  
Assumption checking 
There are three sets of assumptions for this approach: assumptions for instrumental variable 
analysis26, assumptions for causal mediation analysis,27 and assumptions to combine instrumental 
variable analysis with causal mediation analysis.28 The assumptions for instrumental variable 
analysis were checked in Chapter 3, so here we will discuss the other sets of assumptions. 
B. Assumptions for causal mediation analysis27 
a. No bidirectional associations: the bidirectional associations, inflammatory responses to 
DNA methylation, and from inflammatory responses to smoking were assessed using the 
reciprocal Mendelian randomization approach.29 The reciprocal MR approach is similar 
to the original MR approach except that it is used to investigate whether there is an 
inverse association. To examine associations from inflammatory markers to smoking, and 
from inflammatory markers to DNA methylation, we first identified appropriate 
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instrument SNPs for log(CRP), log(IL-6), log(IL-18), and fibrinogen. Genome-wide 
association studies (GWAS) have identified SNPs that are associated with serum CRP30-
32, IL-633, 34, IL-1835, 36, and fibrinogen levels37-40. The SNPs consistently found in GWAS 
were located in CRP30-32; IL6, and IL6R32, 33; IL18, and BCO235, 36; FGA, FGB, and 
FGG37-40 genes, respectively. We investigated the genes ±10kb to identify the most 
significantly associated SNPs with each inflammatory marker level, and used them as 
instrument SNPs for the reciprocal MR approach. 
b. No interaction effect of exposure and mediator on outcome: to check this assumption, the 
interaction effect of smoking and DNA methylation on inflammatory markers was 
assessed using the linear mixed effects model (Equation 4.1). The significance of the 
interaction term was assessed using a Wald test. 
𝐼𝐼𝐸𝐸𝐼𝐼𝑙𝑙𝑙𝑙𝑡𝑡𝑡𝑡𝑙𝑙𝑡𝑡𝑐𝑐𝑐𝑐𝑦𝑦 𝑡𝑡𝑙𝑙𝑐𝑐𝑠𝑠𝑙𝑙𝑐𝑐= 𝛽𝛽0 + 𝛽𝛽1 ∗ 𝑆𝑆𝑡𝑡𝑐𝑐𝑠𝑠𝑡𝑡𝐸𝐸𝑙𝑙𝑖𝑖𝑖𝑖 + 𝛽𝛽2 ∗ 𝐷𝐷𝑆𝑆𝐷𝐷 𝑡𝑡𝑙𝑙𝑡𝑡ℎ𝑦𝑦𝑙𝑙𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝐸𝐸 𝑙𝑙𝑙𝑙𝑐𝑐𝑙𝑙𝑙𝑙𝑐𝑐𝑖𝑖𝑖𝑖+ 𝛽𝛽3 ∗ 𝑆𝑆𝑡𝑡𝑐𝑐𝑠𝑠𝑡𝑡𝐸𝐸𝑙𝑙𝑖𝑖𝑖𝑖 ∗ 𝐷𝐷𝑆𝑆𝐷𝐷 𝑡𝑡𝑙𝑙𝑡𝑡ℎ𝑦𝑦𝑙𝑙𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝐸𝐸 𝑙𝑙𝑙𝑙𝑐𝑐𝑙𝑙𝑙𝑙𝑐𝑐𝑖𝑖𝑖𝑖 + 𝛽𝛽4 ∗ 𝑙𝑙𝑙𝑙𝑙𝑙𝑖𝑖𝑖𝑖 + 𝛽𝛽5
∗ 𝑙𝑙𝑙𝑙𝐸𝐸𝑙𝑙𝑙𝑙𝑐𝑐𝑖𝑖𝑖𝑖 + 𝛽𝛽6 ∗ 𝐶𝐶𝐷𝐷8𝑇𝑇𝑖𝑖𝑖𝑖 +  𝛽𝛽7 ∗ 𝐶𝐶𝐷𝐷4𝑇𝑇𝑖𝑖𝑖𝑖 + 𝛽𝛽8 ∗ 𝑆𝑆𝑁𝑁𝑖𝑖𝑖𝑖 + 𝛽𝛽9 ∗ 𝐵𝐵𝑐𝑐𝑙𝑙𝑙𝑙𝑙𝑙𝑖𝑖𝑖𝑖+ 𝛽𝛽10 ∗ 𝑀𝑀𝑐𝑐𝐸𝐸𝑐𝑐𝑖𝑖𝑖𝑖 + 𝛽𝛽11 ∗ 𝐺𝐺𝑐𝑐𝑙𝑙𝐸𝐸𝑖𝑖𝑖𝑖 + 𝑢𝑢𝑖𝑖 + 𝜀𝜀𝑖𝑖𝑖𝑖   (𝐸𝐸𝐸𝐸𝑢𝑢𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝐸𝐸 4.1) 
where inflammatory markers are log(CRP), log(IL-6), log(IL-18), and fibrinogen. 
C. Assumptions for combining instrumental variable analysis with causal mediation analysis41 
a. Sequential ignorability28 means that the exposure should be statistically independent of 
mediators and outcomes, and the mediator should be statistically independent of the 
outcome given exposure and confounders. Using instrumental variables for the exposure 
and the mediator satisfies the first condition but not the second condition necessarily. If 
there is another mediator (X) in the pathway which either has a causal effect on or is 
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influenced by the mediator of interest, the second condition is not met (Figure 4.2). It is 
possible that other DNA methylation sites mediating smoking and inflammation are 
associated with the DNA methylation site of interest. The variable X can also be a 
confounder between the mediator and the outcome that is affected by the exposure. 
Cigarette smoking is found to be associated with an elevated level of peripheral blood 
leukocytes.42 Hence, cell proportions, which are affected by cigarette smoking and are 
confounders in the association between DNA methylation and inflammation, are also an 
example of X.  
 
Figure 4.2. The example of violation of sequential ignorability. Rectangular boxes represent 
variables of interest and arrows represent causal relationships. SNP S is an instrument for 
smoking status and SNP C is an instrument for DNA methylation of a CpG site (Me-CpG). 
When there is another mediator (X) in the pathway which either has a causal effect on or is 
influenced by the mediator of interest, the error terms of the mediator of interest and the outcome 
will not be independent. The violation of this assumption can be assessed using a sensitivity 
analysis that tests whether the correlation of the two error terms is significantly different from 
zero.28     
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Standardization 
Because of poor convergence of the structural equation modeling (SEM) method, the effects of 
age and gender were eliminated by obtaining residuals from either logistic mixed effect 
modeling or linear mixed effect modeling. All the residuals were standardized to follow the 
normal distribution with mean of zero and standard deviation of one, N(0,1), for more intuitive 
interpretation. 
Structural equation modeling (SEM) 
The path diagram can be transformed to a path model using software for SEM. The network MR 
method was implemented using Stata 13.43 
Results 
Study population descriptive 
The total of 848 African-Americans in GENOA have both measured genotypes and DNA 
methylation levels and were included in the analysis. The mean age was 67 years (standard 
deviation (SD) = 7 years), and 72% of the population were women. In this study population, 11% 
were current smokers, 30% were previous smokers, and 59% were never smokers. The majority 
of the study participants have been diagnosed for hypertension (77%), as expected (Table 4.1).   
Assumption checking 
B. Assumptions for causal mediation analysis27 
a. No bidirectional association 
i. No bidirectional association between smoking and DNA methylation: we investigated 
the bidirectional effect using reciprocal MR. After applying a Bonferroni correction 
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(threshold = 0.05/15 = 0.0033), cg13633560 on LRRC32 gene, cg03636183 on 
F2RL3 gene, cg19859270 on LRRC32 gene, and cg17791651 on POU3F1 gene were 
significantly associated with current smoking status (Table 4.2).  
ii. No bidirectional association between DNA methylation and inflammatory markers 
including log(CRP), log(IL-6), log(IL-18), and fibrinogen: After applying Bonferroni 
correction (threshold = 0.05/4 = 0.0125), log(CRP) levels were significantly 
associated with the DNA methylation levels of cg19859270 on GPR15 gene (Table 
4.3). Even though the p-values did not satisfy the threshold, log(IL-6) levels were 
marginally associated with the DNA methylation levels of cg19859270 on GPR15 
gene (p=0.06), and log(IL-18) levels were associated with cg03636183 on F2RL3 
gene (p=0.04) and cg14223444 on NCBP1 gene (p=0.05) (Table 4.4-4.6).  
iii. No bidirectional association between smoking and inflammatory markers. After 
applying Bonferroni correction (threshold = 0.05/4 = 0.0125), none of the 
inflammatory markers were associated with current smoking status (Table 4.7). 
However, all four inflammatory markers were marginally associated with current 
smoking status.  
b. No interaction effect of exposure and mediator on outcome: we tested the interaction 
effects of smoking and DNA methylation on inflammatory markers including log(CRP), 
log(IL-6), log(IL-18), and fibrinogen. After applying Bonferroni correction (thereshold = 
0.05/15 = 0.0033), none of the interaction terms were significant (Table 4.8-4.11). 
However, the interaction between smoking status and DNA methylation levels of 
cg14223444 on NCBP1 gene was close to being significant for log(IL-18)  (P=0.006, 
Table 4.10) 
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C. Assumption for combining instrumental variable analysis with causal mediation analysis 
a. Sequential ignorability: the correlation between the error terms of DNA methylation and 
inflammatory marker levels were checked. None of them reject the null hypothesis of 
zero correlation with an alpha level of 0.05. 
Direct and indirect effects 
We evaluated both the direct and indirect effects of smoking on inflammatory markers 
considering DNA methylation as a mediator. In our previous study (Aim 2), we identified the 
associations between smoking status and DNA methylation levels of cg03636183 on F2RL3 
gene, and cg03636183 and log(IL-18) levels. In this study, we reevaluated the effect in 
consideration of both direct and indirect effects through DNA methylation levels of cg03636183 
(Table 4.12). The direct effects of smoking were significant for log(CRP), log(IL-6), and 
fibrinogen but not for log(IL-18) levels. The indirect effects of smoking through DNA 
methylation were significant for all the four inflammatory markers. However, when the indirect 
effect was decomposed to the effects from smoking to DNA methylation and from DNA 
methylation to inflammatory markers, the second effect was only significant for log(IL-18), 
which is consistent with the results from the Aim 2. The estimate of the indirect effect on log(IL-
18) was twice the estimate for the direct effect.   
 We also reevaluated the effect of smoking on inflammatory markers in consideration of 
both direct and indirect effects through DNA methylation levels of cg13500388 on CBFB gene 
(Table 4.13). In our previous study (Aim2), we identified the associations from smoking status 
to DNA methylation levels of cg13500388 on CBFB gene, and from the CpG site to log(CRP) 
levels. When both direct and indirect effects were considered, there was a significant direct effect 
of smoking for log(CRP). This suggests that smoking confounds the association between the 
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DNA methylation levels of cg13500388 and log(CRP) levels. Hence, when the direct effect of 
smoking was considered, the effect from the DNA methylation levels of cg13500388 to log(CRP) 
levels was no longer statistically significant.  
Extension to subclinical markers of cardiovascular diseases 
The identified path of smoking, cg03636183 on F2RL3, and log(IL-18) was extended to include 
selected subclinical markers of cardiovascular disease such as left ventricular ejection fraction 
(LVEF) and left ventricular mass index (LVMI). The indirect path did not have a significant 
effect on LVEF (Figure 4.3). On the other hand, the indirect path had a significant effect on the 
LVMI (Figure 4.4).  
 
Figure 4.3 Estimates of the path analysis of smoking, cg03636183 on F2RL3, log(IL-18), 
and left ventricular ejection fraction (LVEF). Boxes represent each of the variables 
considered and arrows represent directed effects. Smoking, cg03636183, log(IL-18) and 
LVEF were standardized to follow N(0,1). The numbers in the arrow represent estimate, 95% 
confidence interval, and p-value. Red color indicates significant estimates and blue color 
indicates non-significant estimates. 
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 Figure 4.4 Estimates of the path analysis of smoking, cg03636183 on F2RL3, log(IL-18), 
and left ventricular mass index (LVMI). Boxes represent each of the variables considered 
and arrows represent directed effects. Smoking, cg03636183, log(IL-18) and LVMI were 
standardized to follow N(0,1). The numbers in the arrow represent estimate, 95% 
confidence interval, and p-value. Red color indicates significant estimates and blue color 
indicates non-significant estimates. 
 
When we investigated the total effect of smoking on LVEF and LVMI, the total effect was not 
significant (Table 4.14). We would be able to identify the indirect path using this approach that 
would not be identified using conventional regression based approaches.  
Discussion 
We investigated both direct and indirect effects from smoking to inflammatory markers mediated 
through DNA methylation. The significant mediated effect of cg03636183 on F2RL3 was 
consistent with the results from the two-step epigenetic MR approach8, and the mediated effect 
was also associated with LVMI. However, we did not find other significant mediated effects. It 
may be because of violation of assumptions required for causal mediation analysis, because of 
low statistical power, or because there are no other mediated effects.  
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 When we checked the assumptions, we identified some bidirectional effects using 
reciprocal MR. The inflammatory markers had bidirectional effects on the smoking status. It may 
be because individuals who experience symptoms or who are diagnosed for a disease are often 
recommended to or voluntarily stop smoking. Both DNA methylation and inflammatory markers 
change due to external exposures. Therefore, it is also possible that inflammatory markers also 
have bidirectional effects on DNA methylation. It is less likely, but possible, that DNA 
methylation levels have bidirectional effects on smoking status.  In fact, behavior such as 
substance use, learning, parenting, and stress can be affected by epigenetic modifications.44 
Recent findings in animal studies showed that epigenetic modification has an effect on behavior 
as a response to environmental exposure.45  
 We also checked the interaction effects between smoking status and DNA methylation 
levels. The DNA methylation level of cg14223444 on NCBP1 gene had a significant interaction 
with smoking status on log(IL-18) levels. The slopes of the association between cg14223444 
levels and log(IL-18) levels were significantly different between smokers and non-smokers 
(estimate = -0.45, p=0.006). This is a good example of gene by environment interaction and it 
suggests that DNA methylation is not just a mediator but may interact with environmental 
exposure. It suggests that the role of DNA methylation is not limited to a mediator, and other 
roles and interaction effects should also be carefully considered.  
The linearity assumption in the relationship among variables is required for SEM. 
However, the relationships between variables in genetic or epidemiology studies are often not 
linear. For example, SNPs that were used as instruments may have dominant or recessive effects 
rather than the assumed additive effects, and the age effect is often quadratic in epidemiology 
studies. To avoid bias in estimates, the basic assumptions should be carefully checked.  
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When the assumptions are satisfied, this approach provides extensibility. By using SEM, 
this approach can incorporate diverse path models. Taking advantage of SEM, we extended our 
study to subclinical markers of cardiovascular disease and we identified the directed path of 
smoking->cg03636183->log(IL-18)->LVMI. Implementing this approach to epidemiologic and 
genetic data may further explain genetic and/or biological mechanisms behind complex diseases 
such as cardiovascular disease.  
 GENOA is a cohort study of individuals with a personal history or family history of 
hypertension.  In the current study, we considered only the African American participants in 
GENOA and used data only from the second examination, thus, the data are cross-sectional.  To 
provide confirmation of the causal path, this should be further evaluated in a longitudinal study 
setting. In addition, the results may not be generalizable to other ethnic groups.  
 In conclusion, the application of network MR and the extension to include more complex 
paths provides the opportunity to better understand the relations among various factors that 
influence subclinical measures of CVD. These approaches can be applied to other risk factors in 
addition to smoking and inflammation for CVD to better understand the role of DNA 
methylation. 
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Tables 
Table 4.1 Descriptive characteristics of GENOA Jackson study population (N=848) at 
Phase 2 Examination. 
Continuous variables N Mean SD 
Age at examination (years) 848 67 7 
Height (cm) 844 168 9 
Weight (kg) 844 88 18 
Body Mass Index (kg/m2) 844 31 6 
Pack years 348 25 22 
Age started smoking 348 20 6 
Age quitted smoking 252 48 12 
Alcohol (number of drinks/week) 122 4 4 
Education (years) 848 12 4 
Systolic blood pressure (sitting, mmHg) 848 154 22 
Diastolic blood pressure (sitting, mmHg) 848 92 12 
Pulse pressure (sitting, mmHg) 848 62 18 
C reactive protein (mg/L) 821 6 7 
Fibrinogen (mg/dL) 823 369 81 
Interleukin-6 (pg/ml) 741 10 7 
Interleukin-18 (pg/ml) 735 72 45 
High density lipoprotein (mg/dL) 848 59 18 
Low density lipoprotein (mg/dL) 848 121 38 
Lipid lp(a) (mg/dL) 823 63 51 
Left ventricular ejection fraction 821 61 8 
Left ventricular mass 822 163 48 
Left ventricular mass index 819 40 11 
Number of siblings  diagnosed for hypertension before age of 60 682 3 2 
Categorical variables  N % 
Female  610 72% 
Current smoker  96 11% 
Previous smoker  252 30% 
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Never smoker  500 59% 
Currently taking blood pressure control medication  634 75% 
Ever diagnosed for hypertension  661 78% 
Ever diagnosed for heart attack or MI  43 5% 
Ever diagnosed for diabetes  249 29% 
Ever diagnosed for cancer  71 8% 
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Table 4.2 Results of reciprocal Mendelian randomization from DNA methylation to 
smoking status. 
CpG site Gene 
Instrument 
SNP 
F-value Estimate SE P 
cg13633560 LRRC32 rs4945097 40 -1.88 0.48 0.0001 
cg03636183* F2RL3 rs2227341 505 -0.58 0.17 0.0008 
cg19859270 GPR15 rs6790026 3 -6.98 2.10 0.0010 
cg17791651 POU3F1 rs34860389 31 -1.28 0.39 0.0011 
cg03330058 ABTB1 rs7627836 155 -0.98 0.34 0.0046 
cg26259865* ZG16B rs11076844 31 -2.04 0.75 0.0072 
cg01500140 LIM2 rs10409027 14 0.78 0.38 0.0410 
cg04983977 GPR25 rs2292099 4 1.87 0.98 0.0563 
cg00353953* ZNF384 rs35787939 22 -1.54 0.92 0.0961 
cg13500388 CBFB rs8048014 630 -0.52 0.33 0.1148 
cg03340878* OR2B6 rs276364 9 -0.96 0.65 0.1442 
cg13668129* HNRNPUL1 rs12980267 7 -1.42 1.21 0.2407 
cg11314684* AKT3 rs10157763 31 -0.78 0.85 0.3563 
cg14223444* NCBP1 rs60028882 237 -0.51 0.64 0.4230 
cg13745870* SPATA12 rs9857168 8 -0.44 0.76 0.5626 
*Because the SAS GLIMMIX procedure did not converge, the sibship effect was modeled as 
repeated measurements instead of a random effect. ABTB1: ankyrin repeat and BTB (POZ) 
domain containing 1, AKT3:v-akt murine thymoma viral oncogene homolog 3, CBFB: core-
binding factor beta subunit, F2RL3: coagulation factor II (thrombin) receptor-like 3, GPR15: G 
protein-coupled receptor 15, GPR25: G protein-coupled receptor 25, HNRPUL1: heterogeneous 
nuclear ribonucleoprotein U-like 1, LIM2: lens intrinsic membrane protein 2 (19kDa), ZG16B: 
zymogen granule protein 16B, LRRC32: leucine rich repeat containing 32, NCBP1: nuclear cap 
binding protein subunit 1 (80kDa), OR2B6: olfactory receptor, family 2, subfamily B, member 6, 
POU3F1: POU class 3 homeobox 1, SPATA12: spermatogenesis associated 12, ZNF384: zinc 
finger protein 384  
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Table 4.3 Results of reciprocal Mendelian randomization from log(CRP) to DNA 
methylation. 
CpG site Gene Estimate SE Pr > |t| 
cg19859270 GPR15 -0.083 0.03 0.01 
cg03340878 OR2B6 0.039 0.03 0.15 
cg14223444 NCBP1 -0.034 0.03 0.25 
cg13745870 SPATA12 -0.023 0.02 0.30 
cg13668129 HNRNPUL1 0.023 0.02 0.31 
cg04983977 GPR25 0.033 0.03 0.32 
cg13500388 CBFB -0.038 0.05 0.42 
cg26259865 LOC124220 0.026 0.03 0.44 
cg03330058 ABTB1 0.041 0.05 0.45 
cg01500140 LIM2 -0.022 0.03 0.48 
cg11314684 AKT3 -0.014 0.03 0.67 
cg13633560 LRRC32 0.014 0.04 0.75 
cg03636183 F2RL3 0.031 0.10 0.75 
cg00353953 ZNF384 0.009 0.04 0.80 
cg17791651 POU3F1 0.007 0.05 0.90 
ABTB1: ankyrin repeat and BTB (POZ) domain containing 1, AKT3:v-akt murine thymoma viral 
oncogene homolog 3, CBFB: core-binding factor beta subunit, F2RL3: coagulation factor II 
(thrombin) receptor-like 3, GPR15: G protein-coupled receptor 15, GPR25: G protein-coupled 
receptor 25, HNRPUL1: heterogeneous nuclear ribonucleoprotein U-like 1, LIM2: lens intrinsic 
membrane protein 2 (19kDa), ZG16B: zymogen granule protein 16B, LRRC32: leucine rich 
repeat containing 32, NCBP1: nuclear cap binding protein subunit 1 (80kDa), OR2B6: olfactory 
receptor, family 2, subfamily B, member 6, POU3F1: POU class 3 homeobox 1, SPATA12: 
spermatogenesis associated 12, ZNF384: zinc finger protein 384  
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Table 4.4 Results of reciprocal Mendelian randomization from log(IL-6) to DNA 
methylation. 
CpG site Gene Estimate SE Pr > |t| 
cg19859270 GPR15 -0.184 0.10 0.06 
cg01500140 LIM2 0.128 0.09 0.15 
cg13745870 SPATA12 -0.092 0.06 0.15 
cg11314684 AKT3 0.116 0.10 0.24 
cg13500388 CBFB -0.158 0.14 0.26 
cg14223444 NCBP1 0.083 0.09 0.35 
cg13668129 HNRNPUL1 -0.059 0.07 0.38 
cg03330058 ABTB1 -0.117 0.16 0.48 
cg04983977 GPR25 0.054 0.10 0.58 
cg17791651 POU3F1 -0.069 0.16 0.67 
cg13633560 LRRC32 0.034 0.13 0.78 
cg03636183 F2RL3 -0.039 0.30 0.90 
cg26259865 LOC124220 0.012 0.10 0.91 
cg03340878 OR2B6 0.004 0.08 0.96 
cg00353953 ZNF384 -0.001 0.11 0.99 
ABTB1: ankyrin repeat and BTB (POZ) domain containing 1, AKT3:v-akt murine thymoma viral 
oncogene homolog 3, CBFB: core-binding factor beta subunit, F2RL3: coagulation factor II 
(thrombin) receptor-like 3, GPR15: G protein-coupled receptor 15, GPR25: G protein-coupled 
receptor 25, HNRPUL1: heterogeneous nuclear ribonucleoprotein U-like 1, LIM2: lens intrinsic 
membrane protein 2 (19kDa), ZG16B: zymogen granule protein 16B, LRRC32: leucine rich 
repeat containing 32, NCBP1: nuclear cap binding protein subunit 1 (80kDa), OR2B6: olfactory 
receptor, family 2, subfamily B, member 6, POU3F1: POU class 3 homeobox 1, SPATA12: 
spermatogenesis associated 12, ZNF384: zinc finger protein 384  
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Table 4.5 Results of reciprocal Mendelian randomization from log(IL-18) to DNA 
methylation. 
CpG site Gene Estimate Std Pr > |t| 
cg03636183 F2RL3 -0.613 0.29 0.04 
cg14223444 NCBP1 0.168 0.09 0.05 
cg03340878 OR2B6 0.093 0.08 0.24 
cg26259865 LOC124220 -0.100 0.10 0.31 
cg17791651 POU3F1 -0.135 0.16 0.39 
cg13633560 LRRC32 0.104 0.12 0.40 
cg13668129 HNRNPUL1 0.052 0.07 0.43 
cg11314684 AKT3 0.073 0.10 0.45 
cg00353953 ZNF384 0.055 0.10 0.59 
cg03330058 ABTB1 0.076 0.16 0.64 
cg13745870 SPATA12 0.023 0.06 0.72 
cg19859270 GPR15 -0.023 0.09 0.81 
cg04983977 GPR25 0.020 0.10 0.84 
cg01500140 LIM2 0.012 0.09 0.89 
cg13500388 CBFB 0.001 0.14 0.99 
ABTB1: ankyrin repeat and BTB (POZ) domain containing 1, AKT3:v-akt murine thymoma viral 
oncogene homolog 3, CBFB: core-binding factor beta subunit, F2RL3: coagulation factor II 
(thrombin) receptor-like 3, GPR15: G protein-coupled receptor 15, GPR25: G protein-coupled 
receptor 25, HNRPUL1: heterogeneous nuclear ribonucleoprotein U-like 1, LIM2: lens intrinsic 
membrane protein 2 (19kDa), ZG16B: zymogen granule protein 16B, LRRC32: leucine rich 
repeat containing 32, NCBP1: nuclear cap binding protein subunit 1 (80kDa), OR2B6: olfactory 
receptor, family 2, subfamily B, member 6, POU3F1: POU class 3 homeobox 1, SPATA12: 
spermatogenesis associated 12, ZNF384: zinc finger protein 384  
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Table 4.6 Results of reciprocal Mendelian randomization from fibrinogen to DNA 
methylation. 
CpG site Gene Estimate Std Pr > |t| 
cg14223444 NCBP1 -0.0009 0.0005 0.08 
cg03340878 OR2B6 0.0008 0.0004 0.09 
cg19859270 GPR15 -0.0009 0.0005 0.11 
cg03636183 F2RL3 -0.0018 0.0017 0.28 
cg13668129 HNRNPUL1 0.0004 0.0004 0.35 
cg11314684 AKT3 0.0005 0.0005 0.39 
cg17791651 POU3F1 -0.0007 0.0009 0.41 
cg26259865 LOC124220 0.0004 0.0006 0.51 
cg13745870 SPATA12 -0.0002 0.0004 0.54 
cg00353953 ZNF384 0.0003 0.0006 0.59 
cg13500388 CBFB 0.0004 0.0008 0.62 
cg01500140 LIM2 0.0002 0.0005 0.68 
cg03330058 ABTB1 -0.0001 0.0009 0.89 
cg04983977 GPR25 0.0001 0.0006 0.89 
cg13633560 LRRC32 -0.0001 0.0007 0.94 
ABTB1: ankyrin repeat and BTB (POZ) domain containing 1, AKT3:v-akt murine thymoma viral 
oncogene homolog 3, CBFB: core-binding factor beta subunit, F2RL3: coagulation factor II 
(thrombin) receptor-like 3, GPR15: G protein-coupled receptor 15, GPR25: G protein-coupled 
receptor 25, HNRPUL1: heterogeneous nuclear ribonucleoprotein U-like 1, LIM2: lens intrinsic 
membrane protein 2 (19kDa), ZG16B: zymogen granule protein 16B, LRRC32: leucine rich 
repeat containing 32, NCBP1: nuclear cap binding protein subunit 1 (80kDa), OR2B6: olfactory 
receptor, family 2, subfamily B, member 6, POU3F1: POU class 3 homeobox 1, SPATA12: 
spermatogenesis associated 12, ZNF384: zinc finger protein 384  
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Table 4.7 Results of reciprocal Mendelian randomization from inflammatory markers to 
smoking status. 
Inflammatory 
marker 
Instrumental 
SNP 
F-value  
of SNP Estimate Std Pr > |t| 
log(CRP) rs9628671 38 0.704 0.324 0.03 
log(IL-6) rs2069837 6 1.268 0.753 0.09 
log(IL-18) rs11214098 4 2.042 0.902 0.02 
Fibrinogen rs28577061 8 0.010 0.005 0.04 
CRP: C-reactive protein, IL-6: interleukin-6, IL-18: interleukin-18  
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Table 4.8 Estimates of the interaction effect of smoking status and DNA methylation on 
log(CRP) levels. 
CpG site Gene Estimate Std P 
cg04983977 GPR25 0.54 0.32 0.10 
cg00353953 ZNF384 0.38 0.25 0.13 
cg14223444 NCBP1 0.37 0.27 0.17 
cg13745870 SPATA12 0.46 0.38 0.22 
cg26259865 ZG16B 0.25 0.23 0.28 
cg01500140 LIM2 0.20 0.21 0.33 
cg03330058 ABTB1 -0.19 0.20 0.34 
cg03636183 F2RL3 -0.07 0.11 0.52 
cg13500388 CBFB -0.13 0.21 0.53 
cg19859270 GPR15 -0.18 0.29 0.54 
cg13668129 HNRNPUL1 -0.27 0.44 0.54 
cg13633560 LRRC32 0.15 0.24 0.54 
cg11314684 AKT3 -0.17 0.30 0.55 
cg03340878 OR2B6 0.10 0.37 0.79 
cg17791651 POU3F1 -0.02 0.18 0.92 
ABTB1: ankyrin repeat and BTB (POZ) domain containing 1, AKT3:v-akt murine thymoma viral 
oncogene homolog 3, CBFB: core-binding factor beta subunit, F2RL3: coagulation factor II 
(thrombin) receptor-like 3, GPR15: G protein-coupled receptor 15, GPR25: G protein-coupled 
receptor 25, HNRPUL1: heterogeneous nuclear ribonucleoprotein U-like 1, LIM2: lens intrinsic 
membrane protein 2 (19kDa), ZG16B: zymogen granule protein 16B, LRRC32: leucine rich 
repeat containing 32, NCBP1: nuclear cap binding protein subunit 1 (80kDa), OR2B6: olfactory 
receptor, family 2, subfamily B, member 6, POU3F1: POU class 3 homeobox 1, SPATA12: 
spermatogenesis associated 12, ZNF384: zinc finger protein 384  
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Table 4.9 Estimates of the interaction effect of smoking status and DNA methylation on 
log(IL-6) levels. 
CpG site Gene Estimate Std P 
cg13668129 HNRNPUL1 -0.44 0.23 0.06 
cg03636183 F2RL3 0.10 0.06 0.09 
cg01500140 LIM2 -0.18 0.11 0.12 
cg17791651 POU3F1 0.10 0.10 0.30 
cg26259865 ZG16B 0.12 0.13 0.34 
cg19859270 GPR15 0.15 0.16 0.35 
cg13500388 CBFB 0.09 0.11 0.41 
cg11314684 AKT3 -0.13 0.16 0.41 
cg03330058 ABTB1 -0.08 0.11 0.47 
cg13745870 SPATA12 0.09 0.21 0.66 
cg04983977 GPR25 -0.06 0.18 0.75 
cg14223444 NCBP1 0.04 0.15 0.81 
cg00353953 ZNF384 0.03 0.14 0.84 
cg13633560 LRRC32 -0.02 0.13 0.89 
cg03340878 OR2B6 0.01 0.20 0.96 
ABTB1: ankyrin repeat and BTB (POZ) domain containing 1, AKT3:v-akt murine thymoma viral 
oncogene homolog 3, CBFB: core-binding factor beta subunit, F2RL3: coagulation factor II 
(thrombin) receptor-like 3, GPR15: G protein-coupled receptor 15, GPR25: G protein-coupled 
receptor 25, HNRPUL1: heterogeneous nuclear ribonucleoprotein U-like 1, LIM2: lens intrinsic 
membrane protein 2 (19kDa), ZG16B: zymogen granule protein 16B, LRRC32: leucine rich 
repeat containing 32, NCBP1: nuclear cap binding protein subunit 1 (80kDa), OR2B6: olfactory 
receptor, family 2, subfamily B, member 6, POU3F1: POU class 3 homeobox 1, SPATA12: 
spermatogenesis associated 12, ZNF384: zinc finger protein 384  
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Table 4.10 Estimates of the interaction effect of smoking status and DNA methylation on 
log(IL-18) levels. 
CpG site Gene Estimate Std P 
cg14223444 NCBP1 -0.45 0.16 0.006 
cg13633560 LRRC32 -0.33 0.15 0.02 
cg17791651 POU3F1 -0.24 0.11 0.03 
cg03330058 ABTB1 -0.23 0.12 0.06 
cg13500388 CBFB -0.23 0.12 0.07 
cg13668129 HNRNPUL1 -0.43 0.27 0.11 
cg26259865 ZG16B -0.21 0.14 0.15 
cg13745870 SPATA12 0.19 0.23 0.42 
cg11314684 AKT3 -0.12 0.18 0.51 
cg19859270 GPR15 0.11 0.18 0.52 
cg00353953 ZNF384 0.07 0.15 0.65 
cg01500140 LIM2 0.06 0.13 0.67 
cg03340878 OR2B6 -0.09 0.23 0.69 
cg03636183 F2RL3 0.02 0.07 0.75 
cg04983977 GPR25 0.04 0.20 0.86 
ABTB1: ankyrin repeat and BTB (POZ) domain containing 1, AKT3:v-akt murine thymoma viral 
oncogene homolog 3, CBFB: core-binding factor beta subunit, F2RL3: coagulation factor II 
(thrombin) receptor-like 3, GPR15: G protein-coupled receptor 15, GPR25: G protein-coupled 
receptor 25, HNRPUL1: heterogeneous nuclear ribonucleoprotein U-like 1, LIM2: lens intrinsic 
membrane protein 2 (19kDa), ZG16B: zymogen granule protein 16B, LRRC32: leucine rich 
repeat containing 32, NCBP1: nuclear cap binding protein subunit 1 (80kDa), OR2B6: olfactory 
receptor, family 2, subfamily B, member 6, POU3F1: POU class 3 homeobox 1, SPATA12: 
spermatogenesis associated 12, ZNF384: zinc finger protein 384  
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Table 4.11 Estimates of the interaction effect of smoking status and DNA methylation on 
fibrinogen levels. 
CpG site Gene Estimate Std P 
cg13668129 HNRNPUL1 -0.43 0.24 0.07 
cg03636183 F2RL3 0.10 0.06 0.09 
cg01500140 LIM2 -0.18 0.11 0.12 
cg17791651 POU3F1 0.10 0.10 0.30 
cg26259865 ZG16B 0.12 0.13 0.34 
cg19859270 GPR15 0.15 0.16 0.35 
cg13500388 CBFB 0.09 0.11 0.41 
cg11314684 AKT3 -0.13 0.16 0.41 
cg03330058 ABTB1 -0.08 0.11 0.47 
cg13745870 SPATA12 0.09 0.21 0.66 
cg04983977 GPR25 -0.06 0.18 0.75 
cg14223444 NCBP1 0.04 0.15 0.81 
cg00353953 ZNF384 0.03 0.14 0.84 
cg13633560 LRRC32 -0.02 0.13 0.89 
cg03340878 OR2B6 0.01 0.20 0.96 
ABTB1: ankyrin repeat and BTB (POZ) domain containing 1, AKT3:v-akt murine thymoma viral 
oncogene homolog 3, CBFB: core-binding factor beta subunit, F2RL3: coagulation factor II 
(thrombin) receptor-like 3, GPR15: G protein-coupled receptor 15, GPR25: G protein-coupled 
receptor 25, HNRPUL1: heterogeneous nuclear ribonucleoprotein U-like 1, LIM2: lens intrinsic 
membrane protein 2 (19kDa), ZG16B: zymogen granule protein 16B, LRRC32: leucine rich 
repeat containing 32, NCBP1: nuclear cap binding protein subunit 1 (80kDa), OR2B6: olfactory 
receptor, family 2, subfamily B, member 6, POU3F1: POU class 3 homeobox 1, SPATA12: 
spermatogenesis associated 12, ZNF384: zinc finger protein 384  
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Table 4.12 Total, direct and indirect effects of smoking on inflammatory markers mediated 
by cg03636183 on F2RL3 gene. 
Inflammatory 
marker Effect Estimate Std. P 95% CI 
log(CRP) Total effect 0.0329 0.0142 0.0200 0.0052 0.0606 
 
Direct effect 0.0296 0.0141 0.0360 0.0019 0.0574 
 
Indirect effect 0.0033 0.0004 <0.0001 0.0026 0.0040 
 
Smoking -> Methylation -0.0861 0.0095 <0.0001 -0.1047 -0.0676 
 
Methylation -> log(CRP) -0.0381 0.0490 0.4370 -0.1341 0.0580 
log(IL6) Total effect 0.0211 0.0082 0.0100 0.0050 0.0371 
 
Direct effect 0.0176 0.0082 0.0320 0.0015 0.0336 
 
Indirect effect 0.0035 0.0004 <0.0001 0.0027 0.0043 
 
Smoking -> Methylation -0.0863 0.0095 <0.0001 -0.1050 -0.0676 
 Methylation -> log(IL6) -0.0407 0.0294 0.1670 -0.0983 0.0170 
log(IL18) Total effect 0.0147 0.0086 0.0880 -0.0022 0.0316 
 
Direct effect 0.0049 0.0085 0.5660 -0.0118 0.0216 
 
Indirect effect 0.0098 0.0011 <0.0001 0.0076 0.0119 
 
Smoking -> Methylation -0.0850 0.0096 <0.0001 -0.1038 -0.0662 
 
Methylation -> log(IL18) -0.1151 0.0307 0.0002 -0.1752 -0.0549 
Fibrinogen Total effect 3.4017 1.0751 0.0020 1.2945 5.5090 
 
Direct effect 3.4081 1.0751 0.0020 1.3009 5.5153 
 
Indirect effect -0.0064 0.0007 <0.0001 -0.0077 -0.0050 
 
Smoking -> Methylation -0.0862 0.0095 <0.0001 -0.1047 -0.0676 
 Methylation -> Fibrinogen 0.0739 3.7185 0.9840 -7.2143 7.3620 
CRP: C-reactive protein, IL6: interleukin-6, and IL18: interleukin-18 
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Table 4.13 Total, direct and indirect effects of smoking on inflammatory markers mediated 
by cg13500388 on CBFB gene. 
Inflammatory 
marker Effect Estimate Std. P 95% CI 
log(CRP) Total effect 0.0329 0.0135 0.0150 0.0064 0.0595 
 
Direct effect 0.0333 0.0135 0.0140 0.0067 0.0598 
 
Indirect effect -0.0004 0.0001 0.0001 -0.0006 -0.0002 
 
Smoking -> Methylation -0.0156 0.0040 0.0001 -0.0235 -0.0077 
 
Methylation -> log(CRP) 0.0236 0.0949 0.8030 -0.1623 0.2095 
log(IL6) Total effect 0.0213 0.0078 0.0060 0.0060 0.0367 
 
Direct effect 0.0203 0.0078 0.0090 0.0050 0.0356 
 
Indirect effect 0.0011 0.0003 0.0002 0.0005 0.0017 
 
Smoking -> Methylation -0.0152 0.0041 0.0002 -0.0232 -0.0072 
  Methylation -> log(IL6) -0.0719 0.0575 0.2110 -0.1846 0.0408 
log(IL18) Total effect 0.0150 0.0082 0.0690 -0.0012 0.0311 
 
Direct effect 0.0138 0.0082 0.0940 -0.0024 0.0299 
 
Indirect effect 0.0012 0.0003 0.0001 0.0006 0.0018 
 
Smoking -> Methylation -0.0159 0.0041 0.0001 -0.0241 -0.0078 
 
Methylation -> log(IL18) -0.0756 0.0595 0.2040 -0.1923 0.0411 
Fibrinogen Total effect 3.3943 1.0290 0.0010 1.3775 5.4112 
 
Direct effect 3.4460 1.0289 0.0010 1.4294 5.4627 
 
Indirect effect -0.0517 0.0135 0.0001 -0.0781 -0.0253 
 
Smoking -> Methylation -0.0155 0.0040 0.0001 -0.0234 -0.0076 
  Methylation -> Fibrinogen 3.3431 7.2040 0.6430 -10.7765 17.4627 
CRP: C-reactive protein, IL6: interleukin-6, and IL18: interleukin-18 
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Table 4.14 Total, direct and indirect effects of smoking on LVEF and LVMI mediated by 
cg03636183 on F2RL3 gene and log(IL-18) levels. 
Subclinical 
outcome Effect Estimate Std. P 95% CI 
LVEF Total effect 0.0103 0.1094 0.925 -0.2041 0.2246 
 
Direct effect 0.0080 0.1094 0.942 -0.2064 0.2224 
 
Indirect effect 0.0023 0.0003 <0.0001 0.0018 0.0028 
LVMI Total effect 0.1039 0.1391 0.455 -0.1686 0.3765 
 
Direct effect 0.1252 0.1390 0.368 -0.1473 0.3977 
 
Indirect effect -0.0212 0.0024 <0.0001 -0.0260 -0.0165 
LVEF: left ventricular ejection fraction, LVMI: left ventricular mass index. 
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Chapter 5 
Conclusions and future directions 
Overall conclusions 
Complex diseases, such as CVD, are influenced by a combination and interaction of various 
factors. Risk of CVD is affected by many factors including genetic variants, epigenetic 
modification, and environmental exposures. Most studies that tend to focus on genetic variants 
ignore other factors or include them as confounders. In contrast, many studies that focus on 
environmental exposures or behaviors tend to ignore genetic susceptibility among individuals. 
While a major assumption of many studies is that there is no gene by environment interaction, 
evidence exists for such interactions. Evidence for gene by environment interaction implies that 
the outcome for a specific genotype depends on environmental exposure or the outcome for 
environmental exposure differs by genotypes. The environment may be measured directly, for 
example by cumulative lead exposure or self-reported smoking, or more indirectly by epigenetic 
modification in response to environmental exposures. Epigenetic modification occurs as a 
response to changes in environmental and lifestyle factors.1 Thus, epigenetic modification is 
known to explain, in part, the interaction between genes and environmental factors in 
development of various diseases including CVD.2-8 Epigenetic modification may be seen as an 
intermediate biomarker which is a result of the interaction between genes and environmental 
factors.  
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 To further understand biological mechanisms of CVD using gene by environment 
interaction, this dissertation utilized effect modification by candidate genetic polymorphisms and 
mediation analysis using epigenetic modification on measures of inflammation including CRP, 
IL-6, IL-18, and fibrinogen as well as CVD risk markers including pulse pressure, LVEF, and 
LVMI. In Chapter 2, we investigated whether there is evidence for an interaction between VDR 
genetic polymorphisms and cumulative bone lead levels on pulse pressure in unrelated non-
Hispanic White men. In Chapter 3, we examined whether there was evidence for a mediated 
effect of DNA methylation on the relation between smoking and inflammatory markers in 
African American siblings. In Chapter 4, we investigated the causal paths of smoking, DNA 
methylation, and inflammatory markers and extended the approach to include subclinical 
markers of CVD in African American siblings.   
Chapter 2 focused on lead exposure as the environmental measure. Lead (Pb) is known to 
increase the risk of CVD. Lead exposure may also induce endothelial injury and 
atherosclerosis.9-11 The study by Perlstein et al12 suggests that lead accumulation may contribute 
to the increase in pulse pressure, a measure of arterial stiffness, and with clinical cardiovascular 
events. Vitamin D and VDR are involved in arterial stiffness and arterial aging.13, 14 The complex 
of vitamin D and VDR acts as a transcription factor regulating the gene expression of calcium-
binding receptors. Because lead is a divalent cation, lead competes with calcium to bind to 
calcium-binding receptors.15 The VDR genetic variants have been identified as potential genetic 
factors that can influence the absorption, retention and accumulation of lead in the human 
body.16 In Chapter 2, we investigated effect modification by the VDR gene on the association 
between cumulative lead exposure measured by bone lead levels and pulse pressure, a marker of 
arterial stiffness. The study was conducted with longitudinal measures (3,100 observations 
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obtained during up to 20 years of follow up) on 727 participants of the NAS. With an 
interquartile range (IQR) increase in tibia lead (15µg/g), pulse pressure was 2.5 mmHg (95% CI: 
0.4-4.7) greater for the participants with at least one minor allele on Bsm1 compared with the 
participants without the minor frequency allele. With an IQR increase in patella lead (20µg/g), 
pulse pressure was 1.9 mmHg (95% CI: 0.1-3.8) greater for the participants with at least one 
copy of the minor frequency allele in Bsm1 compared with the participants without the minor 
frequency allele. Similar results were found for Taq1. In spite of the changing association 
between bone lead levels and pulse pressure over time, the effect modifications by VDR Bsm1 
and Taq1 genotypes on the association between bone lead levels and pulse pressure persists over 
time. In the present study, we found that individuals with at least one VDR Bsm1 variant had a 
2.5 mmHg greater pulse pressure in relation to every 15 µg/g increase in cumulative (tibia) lead 
exposure. We interpret this as suggesting that individuals with at least one copy of the VDR 
Bsm1 variant allele may have 2.5% to 6% greater risks for CVD mortality for every 15 µg/g 
increase in cumulative lead exposure. Our findings suggest the importance of restricting early 
exposure to lead to avoid its persistent adverse health effects in the subjects’ later life. Since the 
NAS is an older cohort of predominantly white male participants, the findings may not be 
generalizable to women, younger individuals, and other ethnicities. Our observation suggests that 
the VDR gene may modify the toxicokinetics of lead and shed light on biological mechanisms 
behind gene by lead interaction on CVD risk.  These findings support the public health initiatives 
to limit lead exposure to protect even people who are susceptible to greater lead-induced 
elevation in pulse pressure (those who carry VDR Bsm1 or Ta1q1 variants) since lead stays in the 
body for a long period of time and is related to higher levels of arterial stiffness.  Importantly, in 
our study if we had ignored lead exposure in this cohort, there would have been no association 
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between VDR polymorphisms and pulse pressure.  Thus, incorporating VDR polymorphisms by 
lead exposure interactions provided information about the role of these polymorphisms. 
Chapter 3 focused on cigarette smoking and DNA methylation.  Cigarette smoking is a 
well-known risk factor for CVD.17 Activation of inflammation has been suggested as a potential 
mechanism behind the smoking-induced cardiovascular risk.18 Efforts to identify genetic 
components in the biological mechanisms behind cigarette smoking-induced inflammation have 
been extended to EWAS.19-23 Several EWAS identified differentially methylated CpG sites 
related to cigarette smoking status.19-24 However, the role of DNA methylation levels as a 
mediator in the association between cigarette smoking and inflammatory responses has not been 
investigated yet. In Chapter 3, we hypothesized that cigarette smoking is associated with DNA 
methylation levels, and DNA methylation levels are associated with inflammatory responses. We 
implemented the two-step epigenetic MR approach25 to study African American siblings from 
GENOA. We identified CpG sites that respond to smoking exposure and mediate the effect of 
smoking on inflammation. We demonstrated that the current smoking status is associated with 
changes in DNA methylation levels of CpG sites on F2RL3, GPR15, CBFB, and GPR25 genes. 
The methylation level changes of CpG sites on F2RL3 and CBFB genes were associated with the 
changes in the levels of inflammatory markers log(IL-18) and log(CRP), respectively. The 
F2RL3 gene has been found to be associated with platelet activation and perioperative 
myocardial injury,26 post infectious irritable bowel syndrome,27 and gastric cancer.28 The CBFB 
gene makes a beta subunit of core-binding transcription factor and it binds to Runt-related 
transcription factors (RUNX1, 2, and 3) that are involved in hematopoiesis and osteogenesis.29 
The CBFB gene has been found to be associated with breast cancer, prostate and ovarian cancer, 
and acute myeloid leukemia.30-32 The two-step epigenetic MR approach enabled us to identify 
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CpG sites that are involved in the association between an environmental exposure and an 
outcome. This approach can expand our understanding on the role of DNA methylation in 
disease development and provides information on biological mechanisms behind it. The DNA 
methylation levels of the F2RL3 and CBFB genes may provide additional information to assess 
genetically-influenced subject-specific smoking exposure levels. 
Chapter 4 extended the approach of the chapter 3 to include direct effects and subclinical 
markers of CVD. Although the two-step MR is useful to assess an indirect effect that causally 
mediates the exposure-outcome association, it is limited to evaluate the magnitude of the indirect 
effect relative to the total effect. If there are several pathways from smoking to inflammation, it 
is likely that the estimates from the previous approach could be biased because that approach 
assumes the only path is through the mediator of interest. Therefore, it is necessary to evaluate 
the mediated effect by DNA methylation in consideration of the possible direct effect. In Chapter 
4, we combined the two-step epigenetic MR approach with causal mediation analysis, which is 
also known as the network MR approach.33 We also extended the network MR approach for 
more complex causal paths using structural equation modeling (SEM). The direct effects of 
smoking were significant for log(CRP), log(IL-6), and fibrinogen but not for log(IL-18) levels. 
The indirect effects of smoking through DNA methylation were significant for all the four 
inflammatory markers. However, when the indirect effect was decomposed into the effects from 
smoking to DNA methylation and from DNA methylation to inflammatory markers, the second 
effect was only significant for log(IL-18), which is consistent with the results from Chapter 3. 
The estimate of the indirect effect on log(IL-18) was twice the estimate for the direct effect. The 
identified path of smoking, cg03636183 on F2RL3, and log(IL-18) was extended to include 
selected subclinical markers of cardiovascular disease such as LVEF and LVMI. The indirect 
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path had a significant effect on LVMI. The additional information on the DNA methylation 
levels of F2RL3 gene may provide more accurate subject-specific smoking exposure level 
information and help to identify a higher risk group among smokers for CVD.  
Studies on gene by environment interaction may shed light on identifying biological 
mechanisms underlying CVD development. The studies of gene by environment interaction in 
this dissertation, using both directly measured environmental exposures as well as indirectly 
measured environmental exposures, together helped us improve our understanding of the 
epigenetic factors that affect CVD risk markers.  
Limitations  
Replication studies are required for many genetic epidemiologic studies. Continued advances in 
genotyping and sequencing during the last decade enables us to examine tens of millions of 
dense genetic markers simultaneously. This has resulted in extensive numbers of tests and 
multiple testing issues. However, even with a conservative multiple testing correction such as the 
Bonferroni correction, there are still false positive findings due to other factors such as 
confounding. Replication studies are a good way to confirm the findings here. However, there 
are not many longitudinal studies with measurements on bone lead levels that can be used to 
replicate findings from Chapter 2. There are not many studies with measurements on genetics, 
epigenetics, inflammation and measures from echocardiograms that can be used to replicate 
findings from Chapter 3 or 4.  We will continue to seek any available data for replication 
recognizing that it is more likely we will find studies for replication for Aims 2 and 3 than for 
Aim 1. 
 To assess the causal relationship and to distinguish a cause and an effect, observations 
over time are critical. Even though GENOA is a longitudinal cohort study, our study on DNA 
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methylation was done cross-sectionally using Phase II data. DNA methylation information is 
also available in Phase I. However, Phase I data was obtained from the Illumina 
HumanMethylation 450K BeadChip ® using both Type I and Type II probes,34 while Phase II 
data was obtained from Illumina HumanMethylation 27K BeadChip ® using only Type I 
probes.35 The Type I and Type II probes have different biochemical properties,36 therefore, we 
cannot compare DNA methylation levels from Phase I to the those from Phase II. It may be 
possible to compare them by extracting only Type I probes (used for 135,501 CpG sites in the 
450K chip) and normalize them separately from Type II probes. However, it is still questionable 
whether DNA methylation levels obtained from different beadchips are comparable. Another 
limitation of this approach is that we obtained DNA methylation information on only about 400 
subjects in Phase I, compared to 1008 subjects in Phase II. However, it may be still useful for a 
simple analysis that does not require dense methylation markers or a large sample size.   
Future directions 
In Chapters 3 and 4, we restricted the role of DNA methylation to a mediator. However, we 
found evidence suggesting that DNA methylation interacts with genetic markers and there is an 
exchange feedback with inflammatory markers. There is also accumulating evidence from other 
work suggesting an interaction between DNA methylation, histone modification, and its role in 
regulation of gene expression.37 In the future, our study could be extended to investigate the 
diverse role of DNA methylation in disease development by considering other regulators.  
 Our approach in Aims 2 and 3 can be extended to study gene by environment interaction. 
When we observe significantly different relationships between an environmental exposure and 
an outcome by certain genotypes, it indicates evidence of gene by environment interaction. 
Similarly, we can study gene by epigenetically-mediated-environment interaction by 
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investigating whether there exists significant difference in effect sizes of the mediating path by 
genotypes of interest. This approach may extend our understanding of the relationship between 
genotype and DNA methylation as a response to environmental exposures. 
 DNA methylation changes overtime and it is a reversible change.38 We still have a 
limited understanding on when, where, and how DNA methylation occurs, and when, where and 
how DNA methylation reverses in response to environmental exposures. Even though we could 
not obtain a good resolution of more detailed DNA methylation status in our study, sequencing 
techniques to detect the states during reverse DNA methylation exist.39 Information on reverse 
DNA methylation may improve our understanding on the role of DNA methylation in disease 
development and its role as a therapeutic target.  
Information on gene expression levels can provide useful evidence on whether the 
changes in DNA methylation levels have an impact on the mRNA levels. Even though mRNA 
level is not a final phenotype, and there are many post-transcriptional and post-translational 
modifications, mRNA levels are useful to confirm the effect of DNA methylation on gene 
expression. Therefore, incorporating mRNA level data might provide better support for the 
findings.  
 Genetic studies are moving toward capturing a full picture of the genetic complexity. In 
the future, to extend Aim1, genetic polymorphisms other than VDR, such as genes in the iron 
metabolism pathway and the inflammation pathway can be studied.40  In Aims 2 and 3, we 
utilized both genetic and epigenetic information. However, phenotypic variation is determined 
by various factors which are not limited to SNPs and DNA methylation. Histone methylation and 
acetylation also plays an important role in regulation of gene expression.41 There are also many 
other regulators in post-transcriptional and post-translational modifications including 
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microRNAs,42, 43 and lncRNAs.44, 45 In the future, we will move toward integrating information 
on various key regulators, which will improve our understanding of complex mechanisms in 
gene expression and their role in disease development.  
 In particular, CVD is a common and complex disease with multiple risk factors including 
genetic and environmental factors. CVD is complex not only in terms of number of risk factors 
but also in terms of the relationship among the risk factors. The relationship is not limited to 
direct or indirect effects but to feedback effects and more complex forms of relationships. There 
have been efforts to integrate genetic variation, gene expression, and clinical phenotypes using 
systems-based approach.46-48 In the future, systems-based approach may play more important 
role in unraveling the molecular networks underlying complex disease development. 
 The approaches used in all three aims can be applied to other exposures, other genetic 
markers, other measures of DNA methylation, other measures of inflammation as well as other 
measures associated with disease risk, and finally other subclinical measures of disease. 
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